UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )
Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐
Check the appropriate box:
☒ | Preliminary Proxy Statement |
☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
☐ | Definitive Proxy Statement |
☐ | Definitive Additional Materials |
☐ | Soliciting Material Pursuant to Rule 14a-12 |
MYLAN N.V.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
☒ | No fee required. |
☐ | Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. |
(1) | Title of each class of securities to which transaction applies: |
(2) | Aggregate number of securities to which transaction applies: |
(3) | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): |
(4) | Proposed maximum aggregate value of transaction: |
(5) | Total fee paid: |
☐ | Fee paid previously with preliminary materials. |
☐ | Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. |
(1) | Amount Previously Paid: |
(2) | Form, Schedule or Registration Statement No.: |
(3) | Filing Party: |
(4) | Date Filed: |
Mylan
a champion for
Better Health
June 2017
Proxy Statement
2017 Annual Meeting of Shareholders
Mylan
Better Health
For a Better World®
Robert J. Coury
Chairman |
Heather Bresch
Chief Executive Officer |
To Our Shareholders, Employees, Customers, Patients, and Friends:
Mylan is a truly unique organization that has relentlessly executed its strategy over the last decade to create a highly differentiated global company capable of making high quality medicines available to the billions of patients who need them. As one of the worlds leading healthcare companies, Mylan markets more than 7,500 products globally and serves more than 165 countries and territories. As the second largest generics company in the U.S., our medicines filled one out of every 13 prescriptions in the U.S. more than the total filled by Pfizer, GlaxoSmithKline, Johnson & Johnson, AstraZeneca, Merck, Sanofi, and Eli Lilly combined. Even more telling, those prescriptions represent more than 22 billion doses, whose price, on average, was just 25 cents per dose.
PIVOTAL YEAR FOR MYLAN
2016 was an eventful and pivotal year for Mylan. We maintained our multiyear track record of delivering strong financial results. We completed two acquisitions Meda AB and the non-sterile topicals-focused specialty and generics business of Renaissance Acquisition Holdings LLC that further built our scale and breadth from a product and geographic perspective. We also continued executing on the many drivers of our organic growth. Further, we started a conversation in the U.S. about the pressing need for fundamental, meaningful reform of the healthcare system.
STRONG FINANCIAL RESULTS
Revenues totaled $11 billion, an impressive increase of 18% compared to 2015. All of our regions North America, Europe, and Rest of World contributed double-digit sales increases. Further, consistent with Mylans emphasis on product and geographic diversity, six of our ten global therapeutic franchises each delivered revenues of approximately $1 billion: Central Nervous System and Anesthesia, Respiratory and Allergy, Infectious Disease, Cardiovascular, Gastroenterology, and Diabetes and Metabolism.
On a U.S. GAAP basis, our diluted earnings per share (EPS) in 2016 was $0.92, a decrease of 46% compared to 2015. This result was driven by reduced earnings from operations; higher non-operating expenses, including higher interest expense; and a higher average share count, among other items. Partially offsetting these items was our recognition of a $358 million income tax benefit. Adjusted diluted EPS in 2016 was $4.89, a 14% increase compared to 2015. This result was driven by expanded sales and earnings from operations in our core operations along with the contribution from acquisitions. The impact of higher interest expense, a higher average share count, and a higher effective tax rate partially offset the growth in earnings from operations.
1
INTEGRATING MYLAN
Through our organic and inorganic growth initiatives over the last several years, we have achieved broad diversity across our regions; scale across all key customer channels, including generics, brands, and over-the-counter, or OTC, products; and an unmatched commercial and operating platform. We now are focused on leveraging that scale, using our ONE Mylan approach, to continue expanding as we optimize our sales force, bring new products to new countries, and maximize high-potential brands. To make sure we identify and fully execute on synergy opportunities, our top priority through the end of 2018 is to integrate Mylan. So, rather than merely folding recent transactions into our existing structure and processes, were looking for ways to further organize, optimize, and operate our new and expanded company so we can maintain our strong financial track record.
CONTINUED EXECUTION ON ORGANIC GROWTH DRIVERS
We also will keep executing on multiple organic-growth drivers, which represent additional levers we can use to manage our business, successfully withstand headwinds, and deliver on our stated targets. This execution is evidenced, for instance, by the U.S. Food and Drug Administrations (FDA) acceptance of our submissions for two of the 16 biosimilars products in our portfolios. We are targeting an additional six developed-markets biosimilars submissions in 2017, as well as more than 30 submissions for this portfolio in emerging markets. In addition, we continue to work toward getting approval from the FDA to market our generic Advair Diskus®.
CATALYST FOR HEALTHCARE SYSTEM REFORM
While Mylan saw many successes in 2016, our business also faced challenges, particularly in the U.S., where the healthcare system is undergoing extraordinary change. The rapid rise of high-deductible health plans, for instance, has shifted significant out-of-pocket costs to consumers, prompting intense interest in and outrage over the complexities of pharmaceutical pricing. We have been living this reality firsthand with our EpiPen® Auto-Injector.
Americans are rightfully concerned about rising drug prices. This is precisely why we took decisive action with our EpiPen product, launching an authorized generic version at less than half of the brands wholesale acquisition cost. Our unprecedented action, along with enhancements we made to our patient-access programs, will help consumers and provide substantial savings to payors.
Providing people access to high quality pharmaceuticals has been our mission since Mylan was founded in West Virginia more than 55 years ago. We remain committed to doing our part to fight for changes to our healthcare system that make a positive difference in patients lives. And we hope that our experience with EpiPen can serve as a catalyst for change and illuminate the conversation about the need for better transparency and reform throughout the healthcare sector.
DOING WHATS RIGHT, NOT WHATS EASY
In addition to doing well, we focus on doing good, through our social commitment to addressing the worlds challenges. Learn more about our commitment in Social Responsibility at Mylan. The publication is available on our website, Mylan.com.
Making the world a better place takes courage and persistence. So on behalf of Mylans Board of Directors and senior leadership team, we would like to extend our sincere appreciation to our most valuable asset of all: the more than 35,000 talented individuals who make up our global workforce. Each and every one of them knows Mylan for who we really are champions for better health.
2
Finally, we would like to invite our shareholders to attend the companys 2017 annual general meeting of shareholders, which will be held on June 22, 2017, at [●] (CET) at [●].
Sincerely,
Robert J. Coury
Chairman
Heather Bresch
CEO
MYLAN BY THE NUMBERS
More than 7,500 marketed products
More than 1,800 additional new product submissions are pending regulatory approval; more than 6,100 more submissions are planned.
Serve more than 165 countries and territories
Approximately 3,000 scientists and regulatory affairs experts; multiple state-of-the-art R&D centers
Annual production capacity of approximately 80 billion oral solid doses, 1.5 billion complex-product units, and 500 million injectables units
Total investment 2008-2016: ~$2.5 billion in capital expenditure and ~$4.2 billion in U.S. GAAP R&D
Global workforce of more than 35,000
2016 revenues: $11 billion
Therapeutic franchises whose 2016 revenues totaled approximately $1 billion: Central Nervous System and Anesthesia, Respiratory and Allergy, Infectious Disease, Cardiovascular, Gastroenterology, and Diabetes and Metabolism
Ticker: MYL (NASDAQ, TASE)
|
|
3
To Our Shareholders:
2016 was a momentous year for Mylan with a key senior leadership transition and two large acquisitions. As independent stewards of Mylan, we are privileged and honored to have overseen these important events and participated in the strategic development behind managements decision to continue driving long-term value in this manner.
VALUE-DRIVING LEADERSHIP TRANSITION
Our Board views leadership succession planning as a core responsibility and in 2016 the Board executed on a multi-year plan that began in 2012. In June 2016, our long-time Executive Chairman Robert Coury ended his role as an executive officer. During the 15-year period in which Mr. Coury led the Company as both Executive Chairman and, prior to that role, as Chief Executive Officer, he has served as a key architect in helping Mylan become a global leader in the generic and specialty pharmaceutical industry. Shareholders have conveyed their support for the Boards belief that his continued role as non-executive Chairman of the Board is important to the Companys efforts to drive shareholder value and grow our voice in the important evolution of the U.S. healthcare system.
We thank Mr. Coury for his years of dedicated service as a Mylan executive and are reassured by his commitment to remain active at the Company as non-executive Chairman. Under our new arrangement, Mr. Coury has agreed to serve as Chairman for at least five years and will intently focus, with the Mylan Board and in collaboration with the management team, on the strategy for Mylan for the next decade and beyond.
COMMITMENT TO SHAREHOLDER ENGAGEMENT
As Mylan continues to drive long-term shareholder value and benefit all its stakeholders in an evolving healthcare environment, our Board has made shareholder engagement a priority. To hear our shareholders perspectives and answer questions about our leadership change, corporate governance, executive compensation, and sustainability initiatives, both our Chairman and certain independent directors engaged directly with several of our top investors during 2016. The Board continues to find this initiative enlightening and informative and, as such, plans to continue shareholder outreach in 2017.
More information about our engagement with shareholders can be found in the Compensation Discussion and Analysis section of the proxy.
CREATING ALIGNMENT AND RETURN ON LEADERSHIP
The key philosophy behind Mylans compensation programs is to drive maximum returns for Company stakeholders on leadership. Our Board has overseen the design and execution of the compensation programs to drive focus on long-term, sustainable value creation. This compensation strategy has been deliberately undertaken by the Board with the full understanding that it has sometimes been different from conventional practices and is not rigidly tied to standard market data and policies. During the important transition year of 2016, our Board was focused on ensuring Mr. Courys continued commitment to the Company for at least five years and designed long-term compensation for him that further strengthens his alignment with our long-term shareholders. With respect to our top executives, we structured executive compensation to be strongly performance-based against relevant and rigorous short- and long-term financial, business, and market metrics.
Additional details of our compensation programs are found in the Compensation Discussion and Analysis.
1
BOARD COMPOSITION AND NEW DIRECTORS
We are committed to maintaining a skilled and engaged Board that reflects principles of diversity and independence. Our Boards average tenure is close to that of other large publicly traded companies. Further, the varied experience and tenure on the Board ensures that we have a blend of newer and more seasoned directors who bring valuable perspectives to our boardroom. The current composition of our Board demonstrates our commitment to gender and ethnic diversity, with women and ethnic minorities holding 5 of 13 Board seats. We continue to seek and attract new director candidates who will keep our Boards skillset strong and its overall composition diverse.
Thank you for the trust you place in us. We are honored and appreciative of the opportunity to serve Mylan as independent directors.
Sincerely,
Independent Directors of Mylan N.V.
OUR MISSION
At Mylan, we are committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we:
Innovate to satisfy unmet needs
Make reliability and service excellence a habit
Do whats right, not whats easy
Impact the future through passionate global leadership
A UNIQUE GLOBAL COMPANY
Relentless execution of Mylans strategy over the last decade has produced a highly differentiated global company capable of making high quality medicines available to everyone who needs them. Among our many strengths:
Extensive product portfolio: We have one of the industrys broadest and most diverse portfolios, with more than 7,500 marketed products.
Expansive commercial footprint: We offer our products in more than 165 countries and territories. Our global sales force of more than 5,000 calls on approximately 60,000 customers.
World-class supply chain: Our proven supply chain helps ensure that our medicines are available whenever and wherever needed from large cities to rural outposts, and in developed and developing nations alike. We credit it with helping us, for instance, supply affordable antiretroviral medicine to approximately half of all people on treatment for HIV/AIDS in developing countries.
Substantial research and development capabilities: We have a strong track record of developing new products, particularly complex and difficult-to-formulate medicines. We employ approximately 3,000 scientists and regulatory affairs experts globally who continually innovate, and we partner with other leading companies to augment our expertise.
Powerful, high quality manufacturing platform: Our 50 plants around the world manufacture tens of billions of doses of medicine annually, and each site adheres to stringent quality standards, regardless of location. Further, our platform is significantly vertically integrated meaning we produce nearly all of our active pharmaceutical ingredients and finished products allowing us to rigorously manage per-dosage costs. We currently make internally 80% of the volumes we sell.
|
2
Mylan Proxy Statement
2017 Annual General Meeting of Shareholders
|
June 22, 2017
|
PRELIMINARY SUBJECT TO COMPLETION
Dear Mylan N.V. Shareholders:
You are cordially invited to attend the annual general meeting of shareholders of Mylan N.V. (Mylan or the Company), which will be held on Thursday, June 22, 2017, at [●] Central European Time (CET), [●].
During the annual general meeting, shareholders will be asked to vote on the appointment of directors; the adoption of the Dutch annual accounts for fiscal year 2016; the ratification of the selection of Deloitte & Touche LLP as Mylans independent registered public accounting firm for fiscal year 2017; the instruction to Deloitte Accountants B.V. for the audit of Mylans Dutch statutory annual accounts for fiscal year 2017; the approval, on an advisory basis, of the compensation of the named executive officers of the Company (the Say-on-Pay Vote); the frequency, on an advisory basis, of the Say-on-Pay Vote; and authorization of Mylan N.V.s Board of Directors to acquire ordinary shares and preferred shares in the capital of Mylan (each a Proposal and together the Proposals).
The enclosed Notice of Annual General Meeting of Shareholders and Proxy Statement contain details regarding each of the Proposals, the annual general meeting and other matters. We encourage you to review these materials carefully.
Thank you for your continued support of Mylan. We look forward to seeing you on June 22nd.
Very truly yours,
| ||
Robert J. Coury Chairman Mylan N.V. |
Heather Bresch Chief Executive Officer Mylan N.V. |
The accompanying proxy statement is dated [●], 2017 and is first being mailed to the shareholders of Mylan on or about [●], 2017.
Mylan N.V. Building 4, Trident Place Mosquito Way, Hatfield, Hertfordshire, AL10 9UL England +44 (0) 1707 853 000 |
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
To Be Held On June 22, 2017
On behalf of the Mylan N.V. Board of Directors (the Mylan Board), we are pleased to convene the annual general meeting of shareholders of Mylan N.V. (Mylan or the Company), which will be held at [●] on June 22, 2017 at [●] Central European Time (CET), with the following agenda:
| Opening of the annual general meeting |
| Appointment of directors (voting items) |
| Explanation of remuneration policy for the Mylan Board (discussion item) |
| Mylan Board report for fiscal year 2016 (discussion item) |
| Adoption of the Dutch statutory annual accounts for fiscal year 2016 (voting item) |
| Ratification of the selection of Deloitte & Touche LLP as the Companys independent registered public accounting firm for fiscal year 2017 (voting item) |
| Instruction to Deloitte Accountants B.V. for the audit of the Companys Dutch statutory annual accounts for fiscal year 2017 (voting item) |
| Approval, on an advisory basis, of the compensation of the named executive officers of the Company (the Say-on-Pay Vote) (voting item) |
| Advisory vote on the frequency of the Say-on-Pay Vote (voting item) |
| Authorization of the Mylan Board to acquire ordinary shares and preferred shares in the capital of the Company (voting item) |
| Questions |
| Closing of the annual general meeting |
No business will be voted on at the annual general meeting except such items as stated in the above-mentioned agenda. Please refer to the accompanying proxy statement for further information with respect to the items as stated in the above-mentioned agenda.
The annual general meeting will be held on June 22, 2017, and May 25, 2017 is the record date (registratiedatum) (the Record Date). The Mylan Board has determined that Mylans shareholders register (the Register) is the relevant register for determination as of the Record Date of the holders of Mylan shares and others with meeting rights who are entitled to attend and, if relevant, vote at the Mylan annual general meeting. The Mylan Board has chosen to apply the Record Date to all Mylan shares, including preferred shares. Those who are holders of Mylan shares or who otherwise have such meeting rights with respect to Mylan shares on the Record Date and who are registered as such in the Register may attend the annual general meeting of shareholders and, if relevant, vote at such meeting in person, or authorize a third party to attend and, if relevant, vote at the meeting on their behalf through the use of a proxy card.
Holders of Mylan ordinary shares and others with meeting rights with respect to Mylan ordinary shares who are not registered in the Register may request, if eligible for registration, to be registered in the Register not later than the Record Date by means of a request sent to Mylan either in writing (such notice to be sent to Mylans office address as set out above to the attention of Mylans Corporate Secretary) or by sending an e-mail to corporatesecretary@mylan.com.
Unless the context otherwise requires, references to (a) Mylan ordinary shareholders refer to both (i) shareholders who on the Record Date are registered in the Register as holders of Mylan ordinary shares and (ii) others with meeting rights under Dutch law with respect to Mylan ordinary shares, who on the Record Date are registered as such in the Register, (b) Mylan preferred shareholders refer to both (i) shareholders who on the Record Date are registered in the Register as holders of Mylan preferred shares and (ii) others with meeting rights under Dutch law with respect to Mylan preferred shares who, on the Record Date, are registered as such in the Register, and (c) Mylan shareholders refer to Mylan ordinary shareholders and Mylan preferred shareholders. As of [●], 2017, no Mylan preferred shares were outstanding. The invitation to attend and vote at the annual general meeting is being extended to such persons and also to the beneficial owners of Mylan ordinary shares held through a broker, bank, trust company, or other nominee.
Beneficial owners of Mylan ordinary shares that are not traded through the Tel Aviv Stock Exchange (TASE) and held through a broker, bank, trust company, or other nominee may not vote the underlying ordinary shares at the Mylan annual general meeting of shareholders unless they first obtain (where appropriate, through the relevant broker, bank, trust company, or other nominee) a signed proxy card from the relevant shareholder who is registered in the Register as the holder on the Record Date of the underlying ordinary shares. In addition, beneficial owners of Mylan ordinary shares must provide proof of ownership, such as a recent account statement or letter from a brokerage firm, bank nominee, or other institution proving ownership on the Record Date.
Beneficial owners of Mylan ordinary shares that are traded through the TASE may not vote the underlying ordinary shares at the Mylan annual general meeting of shareholders unless they first obtain an ownership certificate from the Tel Aviv Stock Exchange Clearing House Ltd. (the TASE Clearing House) member through which the underlying ordinary shares are registered (which you can obtain from your TASE broker) indicating the beneficial ownership of those ordinary shares on the Record Date.
Mylan shareholders and holders of a proxy card to vote Mylan shares who wish to attend and, if relevant, vote in person at the annual general meeting of shareholders must notify Mylan of their plan to attend the meeting no later than [●] Central European Time (CET) on [●], 2017 (the Cut-Off Time), in writing (such notice to be sent to Mylans office address set out above to the attention of Mylans Corporate Secretary). In addition, proper identification, such as a drivers license or passport, must be presented at the meeting. Failure to comply with such notification and identification requirements may result in not being admitted to the meeting.
Proxy cards to vote ordinary shares and preferred shares, in person or otherwise, must be completed and received by Mylan no later than the Cut-Off Time.
For more information, see The Annual General Meeting beginning on page [●] of the accompanying proxy statement.
If you do not expect to attend the annual general meeting in person, you may vote your ordinary shares after the Record Date but no later than the Cut-Off Time by (1) accessing the following Internet website: [●], or (2) calling the following toll-free number: [●], or (3) marking, signing, dating, and returning a proxy card for all of the shares you may vote (for which purpose you may use the postage-paid envelope provided), so that your shares may be represented and voted at the annual general meeting. If you beneficially own Mylan ordinary shares that are traded through the TASE, you may after the Record Date but no later than the Cut-Off Time sign and date, and deliver by mail, e-mail, or fax a proxy card in the form filed by us on MAGNA, the distribution site of the Israeli Securities Authority, at www.magna.isa.gov.il, on [●], 2017, together with a certificate of ownership from the TASE Clearing House member through which your Mylan ordinary shares are registered (which you can obtain from your TASE broker). In each case, if your shares are held through and/or in the name of a broker, bank, trust company, or other nominee, please follow the instructions on the voting instruction card furnished by such broker, bank, trust company, or other nominee, or, if your ordinary shares are traded through the TASE, on the proxy card in the form filed by us on MAGNA.
Please note that if you hold shares in different accounts, it is important that you vote the shares represented by each account.
The Mylan Board unanimously recommends that Mylan shareholders vote FOR the appointment of each director; FOR the adoption of the Dutch annual accounts for fiscal year 2016; FOR the ratification of the selection of Deloitte & Touche LLP as the Companys independent registered public accounting firm for fiscal year 2017; FOR the instruction to Deloitte Accountants B.V. for the audit of the Companys Dutch statutory annual accounts for fiscal year 2017; FOR the approval, on an advisory basis, of the compensation of the named executive officers of the Company; and FOR, on an advisory basis, one year as the frequency for the Say-on-Pay Vote; and FOR the authorization of the Mylan Board to acquire ordinary shares and preferred shares in the capital of the Company.
Please note that this Notice of Annual General Meeting does not purport to address all of the information relevant to the meeting or the voting items. The Mylan Board therefore encourages you to read the accompanying proxy statement carefully and in its entirety. If you have any questions concerning the voting items, would like additional copies or need help voting your Mylan shares, please contact Mylans proxy solicitor:
Innisfree M&A Incorporated
501 Madison Avenue
New York, NY 10022
+1 (877) 750-9499 (toll free)
+1 (212) 750-5833 (banks and brokers)
By Order and on behalf of the Mylan N.V. Board, |
Joseph F. Haggerty Corporate Secretary Mylan N.V. |
Important notice regarding the availability of proxy materials for the shareholder meeting to be held on June 22, 2017:
The 2017 Proxy Statement, the 2016 Annual Report on Form 10-K and the amendment thereto, the Mylan Board report for fiscal year 2016 and the Dutch annual accounts for fiscal year 2016 are available at mylan.com/investors.
Proxy Statement
This proxy statement (the Proxy Statement) is dated [●], 2017 and is being furnished (together with the enclosed proxy card) in connection with the solicitation of proxies at the direction of the Board of Directors (the Mylan Board) of Mylan N.V. (Mylan or the Company) for use at the annual general meeting of shareholders of Mylan to be held on June 22, 2017 in connection with the appointment of directors; the adoption of the Dutch annual accounts for fiscal year 2016; ratification of the selection of Deloitte & Touche LLP (Deloitte) as the Companys independent registered public accounting firm for fiscal year 2017; instruction to Deloitte Accountants B.V. for the audit of the Companys Dutch statutory annual accounts for fiscal year 2017; approval, on an advisory basis, of the compensation of the named executive officers of the Company (the Say-on-Pay Vote); the advisory vote on the frequency of the Say-on-Pay Vote; and authorization of the Mylan Board to acquire ordinary shares and preferred shares in the capital of the Company (each a Proposal and together the Proposals).
Forward-Looking Statements
This Proxy Statement and Shareholder Letter contain forward-looking statements. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include, without limitation, statements about the acquisition of Meda AB (publ.) (Meda) by Mylan (the Meda Transaction), Mylans acquisition (the EPD Transaction) of Mylan Inc. and Abbott Laboratories (Abbott) non-U.S. developed markets specialty and branded generics business (the EPD Business), the potential benefits and synergies of the EPD Transaction and the Meda Transaction, future opportunities for Mylan and products, and any other statements regarding Mylans future operations, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, competition, and other expectations and targets for future periods. These may often be identified by the use of words such as will, may, could, should, would, project, believe, anticipate, expect, plan, estimate, forecast, potential, intend, continue, target, and variations of these words or comparable words. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the ability to meet expectations regarding the accounting and tax treatments of the EPD Transaction and the Meda Transaction; changes in relevant tax and other laws, including but not limited to changes in the U.S. tax code and healthcare and pharmaceutical laws and regulations in the U.S. and abroad; actions and decisions of healthcare and pharmaceutical regulators; the integration of the EPD Business and Meda being more difficult, time-consuming, or costly than expected; operating costs, customer loss, and business disruption (including, without limitation, difficulties in maintaining relationships with employees, customers, clients, or suppliers) being greater than expected following the EPD Transaction and the Meda Transaction; the retention of certain key employees of the EPD Business and Meda being difficult; the possibility that Mylan may be unable to achieve expected synergies and operating efficiencies in connection with the EPD Transaction, the Meda Transaction, and the December 2016 announced restructuring program in certain locations, within the expected time-frames or at all and to successfully integrate the EPD Business and Meda; with respect to the Company agreeing to the terms of a $465 million settlement with the U.S. Department of Justice and other government agencies related to the classification of the EpiPen® Auto-Injector and EpiPen Jr® Auto-Injector (collectively, EpiPen® Auto-Injector) for purposes of the Medicaid Drug Rebate Program, the inability or unwillingness on the part of any of the parties to finalize the settlement, any legal or regulatory challenges to the settlement, and any failure by third parties to comply with their contractual obligations; expected or targeted future financial and operating performance and results; the capacity to bring new products to market, including but not limited to where Mylan uses its business judgment and decides to manufacture, market, and/or sell products, directly or through third parties, notwithstanding the fact that allegations of patent infringement(s) have not been finally resolved by the courts (i.e., an at-risk launch); any regulatory, legal, or other impediments to Mylans ability to bring new products to market; success of clinical trials and Mylans ability to execute on new product opportunities; any changes in or difficulties with our inventory of, and our ability to manufacture and distribute, the EpiPen® Auto-Injector to meet anticipated demand; the potential impact of any change in patient
access to the EpiPen® Auto-Injector and the introduction of a generic version of the EpiPen® Auto-Injector; the scope, timing, and outcome of any ongoing legal proceedings, including government investigations, and the impact of any such proceedings on financial condition, results of operations, and/or cash flows; the ability to protect intellectual property and preserve intellectual property rights; the effect of any changes in customer and supplier relationships and customer purchasing patterns; the ability to attract and retain key personnel; changes in third-party relationships; the impact of competition; changes in the economic and financial conditions of the businesses of Mylan; the inherent challenges, risks, and costs in identifying, acquiring, and integrating complementary or strategic acquisitions of other companies, products, or assets and in achieving anticipated synergies; uncertainties and matters beyond the control of management; and inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements, and the providing of estimates of financial measures, in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) and related standards or on an adjusted basis. For more detailed information on the risks and uncertainties associated with Mylans business activities, see the risks described in Mylans Annual Report on Form 10-K for the year ended December 31, 2016, as amended, and our other filings with the Securities and Exchange Commission (the SEC). You can access Mylans filings with the SEC through the SEC website at www.sec.gov, and Mylan strongly encourages you to do so. Mylan undertakes no obligation to update any statements herein for revisions or changes after the filing date of this Proxy Statement.
Reconciliation of Non-GAAP Financial Measures
This Proxy Statement and Shareholder Letter include the presentation and discussion of certain financial information that differs from what is reported under U.S. GAAP. These non-GAAP financial measures, including, but not limited to, adjusted diluted earnings per share (adjusted EPS), adjusted free cash flow, and return on invested capital, are presented in order to supplement investors and other readers understanding and assessment of Mylans financial performance. Management uses these measures internally for forecasting, budgeting, measuring its operating performance, and incentive-based awards. In addition, primarily due to acquisitions, Mylan believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared only in accordance with U.S. GAAP. We believe that non-GAAP financial measures are useful supplemental information for our investors and when considered together with our U.S. GAAP financial measures and the reconciliation to the most directly comparable U.S. GAAP financial measure, provide a more complete understanding of the factors and trends affecting our operations. The financial performance of the Company is measured by senior management, in part, using the adjusted metrics included herein, along with other performance metrics. Managements annual incentive compensation is derived, in part, based on the adjusted EPS metric and the adjusted free cash flow metric. Appendix A to this Proxy Statement contains reconciliations of such non-GAAP financial measures to the most directly comparable U.S. GAAP financial measures. Investors and other readers are encouraged to review the related U.S. GAAP financial measures and the reconciliations of the non-GAAP measures to their most directly comparable U.S. GAAP measures set forth in Appendix A, and investors and other readers should consider non-GAAP measures only as supplements to, not as substitutes for or as superior measures to, the measures of financial performance prepared in accordance with U.S. GAAP.
|
Page | ||
Questions and Answers About The Annual General Meeting and Voting |
1
| |
|
6
| |
6 | ||
6 | ||
6 | ||
7 | ||
7 | ||
7 | ||
7 | ||
8 | ||
8 | ||
9 | ||
9 | ||
10 | ||
10 | ||
10 | ||
|
10
| |
Voting Item 1 Appointment of Directors
|
11
| |
19 | ||
19 | ||
20 | ||
20 | ||
20 | ||
21 | ||
21 | ||
21 | ||
21 | ||
21 | ||
22 | ||
23 | ||
23 | ||
25 | ||
25 | ||
Security Ownership of Directors, Nominees, and Executive Officers |
27 | |
28 | ||
28 | ||
29 |
Page | ||
Voting Item 2 Adoption of Dutch Annual Accounts for Fiscal Year 2016 |
31 | |
32 | ||
32 | ||
32 | ||
33 | ||
34 | ||
35 | ||
35 | ||
61 | ||
62 | ||
64 | ||
65 | ||
66 | ||
67 | ||
67 | ||
67 | ||
68 | ||
68 | ||
69 | ||
73 | ||
Voting Item 6 Advisory Vote on the Frequency of the Say-on-Pay Vote |
74 | |
75 | ||
76 | ||
76 | ||
78 | ||
Proposals for the 2018 Annual General Meeting of Shareholders |
78 | |
79 | ||
79 | ||
79 | ||
Appendix A Reconciliation of Non-GAAP Measures (Unaudited) |
A-1 |
Questions and Answers About the Annual General Meeting and Voting
|
The following questions and answers are intended to address briefly some questions that you, as a Mylan shareholder, may have regarding the matters to be voted on at the 2017 annual general meeting of shareholders (AGM). These questions and answers highlight only some of the information contained in this proxy statement. Mylan urges you to read carefully the entire proxy statement because the information in this section does not provide all the important information with respect to these matters.
Unless the context expressly provides otherwise, this proxy statement describes the rights of Mylan ordinary shareholders to attend and, if relevant, vote at the AGM, including the procedures for convening the AGM and for Mylan ordinary shareholders exercising voting and other rights at such meeting. Generally similar rights apply in respect of Mylan preferred shareholders.
Q: | Why am I receiving this proxy statement? |
A: | You are receiving this proxy statement because you were a Mylan shareholder or beneficial owner of Mylan shares on the Record Date (as defined below) for the AGM. This proxy statement serves as the proxy statement through which the Mylan Board will solicit proxies in connection with the Proposals. |
This proxy statement contains important information about the Proposals, and you should read it carefully and in its entirety. The enclosed voting materials allow you, at your option, to vote your shares without attending the AGM.
You may mark, sign, and date your proxy card and return it in the enclosed postage-paid envelope, or vote over the Internet or by telephone, in accordance with the instructions contained in this proxy statement so that your Mylan ordinary shares may be represented and voted at the AGM. For more information, see the question below entitled How do I vote?.
Q: | When and where will the AGM be held? |
A: | The AGM will be held at [●] on June 22, 2017 at [●] Central European Time (CET). |
Q: | How can I attend the AGM? |
A: | If you wish to attend the AGM in person, please so inform Mylan in writing (such notice to be sent to Mylans office address as set forth in the Notice of Annual General Meeting of Shareholders to the attention of Mylans Corporate Secretary) prior to [●] Central European Time (CET) on [●], 2017 (the Cut-Off Time). |
Beneficial owners of Mylan ordinary shares that are not traded through the Tel Aviv Stock Exchange (TASE) and held through a broker, bank, trust company or other nominee may not vote the underlying ordinary shares at the AGM unless they first obtain (where appropriate, through the relevant broker, bank, trust company or other nominee) a signed proxy card from the relevant shareholder who is registered in the Register as the holder on the Record Date of the underlying ordinary shares. In addition, beneficial owners of Mylan ordinary shares must provide proof of ownership, such as a recent account statement or letter from a brokerage firm, bank nominee, or other institution proving ownership on the Record Date.
Beneficial owners of Mylan ordinary shares that are traded through the TASE may not vote the underlying ordinary shares at the AGM unless they first obtain an ownership certificate from the Tel Aviv Stock Exchange Clearing House Ltd. (the TASE Clearing House) member through which the underlying ordinary shares are registered (which you can obtain from your TASE broker) indicating the beneficial ownership of those ordinary shares on the Record Date.
Proper identification, such as a drivers license or passport, must be presented at the meeting.
page 1
Q: | Who is entitled to vote at the AGM and how many votes do they have? |
A: | Dutch law provides that the record date for the AGM must be 28 days prior to the date of the AGM; thus, the record date is May 25, 2017 (the Record Date). Mylan shareholders who on the Record Date are registered in Mylans shareholder register (the Register) may attend the AGM and, if relevant, vote at such meeting in person or authorize a third party to attend and, if relevant, vote at the meeting on their behalf through the use of a proxy card. |
If you are a beneficial owner of Mylan ordinary shares and hold your shares through a bank, broker, trust company, or other nominee (street name), the relevant institution will send you instructions describing the procedure for instructing the relevant institution as to how to vote the Mylan ordinary shares you beneficially own.
If you wish to vote the Mylan ordinary shares you beneficially own directly either in person at the AGM or by proxy, you must first obtain a signed legal proxy from the bank, broker, trust company or other nominee through which you beneficially own your Mylan ordinary shares, or if you are a beneficial owner of Mylan ordinary shares traded through the TASE, you must obtain a certificate of ownership from the TASE Clearing House member through which your Mylan ordinary shares are registered (which you can obtain from your TASE broker).
As of the close of business on [●], 2017 (the last practicable date prior to the Record Date and the mailing of the proxy statement), there were [●] Mylan ordinary shares and no Mylan preferred shares outstanding and entitled to vote. Each Mylan share is entitled to one vote on each matter properly brought before the AGM. Shareholders do not have cumulative voting rights.
Unless the context otherwise requires, references to (a) Mylan ordinary shareholders refer to both (i) shareholders who on the Record Date are registered in the Register as holders of Mylan ordinary shares and (ii) others with meeting rights under Dutch law with respect to Mylan ordinary shares, who on the Record Date are registered as such in the Register, (b) Mylan preferred shareholders refer to both (i) shareholders who on the Record Date are registered in the Register as holders of Mylan preferred shares and (ii) others with meeting rights under Dutch law with respect to Mylan preferred shares who, on the Record Date, are registered as such in the Register, and (c) Mylan shareholders refer to Mylan ordinary shareholders and Mylan preferred shareholders. The invitation to attend and vote at the AGM is being extended to such persons. Beneficial owners of Mylan ordinary shares are invited to attend the AGM and, if they obtain a legal proxy, or if you are a beneficial owner of Mylan ordinary shares traded through the TASE, a certificate of ownership, as described above, to vote at the AGM.
Q: | What vote is required to adopt each of the Proposals? |
A: | Consistent with established Dutch law and the Companys articles of association, executive directors and non-executive directors are appointed by the general meeting from a binding nomination proposed by the Mylan Board. The proposed candidate specified in a binding nomination shall be appointed provided that the requisite quorum is present or represented at the general meeting, unless the nomination is overruled by the general meeting voting against the appointment of the candidate by a resolution adopted with a majority of at least two-thirds of the votes cast, representing more than half of the issued share capital. In such event, the Mylan Board may draw up a new binding nomination to be submitted at a subsequent general meeting. |
Other than for the appointment of directors, each Proposal requires the affirmative vote of an absolute majority of the valid votes cast at the AGM. A quorum of at least one-third of the issued share capital is separately required for the adoption of each Proposal. If a quorum of at least one-third of the issued share capital is not present or represented with respect to any Proposal, such Proposal cannot be validly adopted at the AGM.
page 2
Q: | How does the Mylan Board recommend that I vote? |
A: | The Mylan Board unanimously recommends that the Mylan shareholders vote FOR the appointment of each director; FOR the adoption of the Dutch annual accounts for fiscal year 2016; FOR ratification of the selection of Deloitte as the Companys independent registered public accounting firm for fiscal year 2017; FOR instruction to Deloitte Accountants B.V. for the audit of the Companys Dutch statutory annual accounts for fiscal year 2017; FOR approval, on an advisory basis, of the compensation of the named executive officers of the Company; FOR, on an advisory basis, one year as the frequency for the Say-on-Pay Vote; and FOR authorization of the Mylan Board to acquire ordinary shares and preferred shares in the capital of the Company. |
Q: | How do I vote? |
A: | Mylan shareholders may cast their votes at the meeting, over the Internet, by submitting a proxy card, or by calling a toll-free number in accordance with the instructions contained in this proxy statement. |
If the ownership of your Mylan ordinary shares is reflected directly on the Register as of the Record Date and you vote by proxy, the individuals named on the enclosed proxy card will vote your Mylan ordinary shares in the manner you indicate. If you do not specify voting instructions, then the proxy will be voted in accordance with the recommendation of the Mylan Board, as described in this proxy statement.
If you are a beneficial owner of Mylan ordinary shares and hold your shares in street name through a bank, broker, trust company, or other nominee, the relevant institution will send you instructions describing the procedure for instructing the relevant institution as to how to vote the Mylan ordinary shares you beneficially own.
Q: | If my shares are held in street name by my broker, will my broker automatically vote my shares for me? |
A: | If you hold your shares in street name, your broker, bank, trust company or other nominee cannot vote your shares on non-routine matters without instructions from you. Each of the Proposals is considered a non-routine matter, other than adoption of the Dutch statutory annual accounts for fiscal year 2016, the ratification of the selection of Deloitte as Mylans independent registered public accounting firm for fiscal year 2017, and the instruction to Deloitte Accountants B.V. for the audit of the Companys Dutch statutory annual accounts for fiscal year 2017 (each of which is considered a routine matter). You should instruct your broker, bank, trust company or other nominee as to how to vote your Mylan ordinary shares, following the directions from your broker, bank, trust company or other nominee provided to you. Please check the voting form used by your broker, bank, trust company or other nominee. |
If you do not give instructions to your broker, bank, trust company or other nominee, the broker, bank, trust company or other nominee will nevertheless be entitled to vote your ordinary shares in its discretion on routine matters and may give or authorize the giving of a proxy to vote the ordinary shares in its discretion on such matters. In such an instance, your shares will be counted for purposes of determining the presence of a quorum with respect to such Proposal. If you do not provide your broker, bank, trust company or other nominee with instructions and your broker, bank, trust company or other nominee submits an unvoted proxy with respect to a Proposal (either because it is non-routine or such broker, bank, trust company or other nominee does not give its discretion with respect to a routine Proposal), your shares will not be counted for purposes of determining the presence of a quorum with respect to that Proposal.
Beneficial owners of Mylan ordinary shares held through a broker, bank, trust company or other nominee may not vote the underlying ordinary shares at the AGM, unless they first obtain (where appropriate, through the relevant broker, bank, trust company or other nominee) a signed proxy card from the relevant shareholder who is registered in the Register as the holder on the Record Date of the underlying ordinary shares, or if you are a beneficial owner of Mylan ordinary shares traded through the TASE, unless you obtain a certificate of ownership from the TASE Clearing House member through which your Mylan ordinary shares are registered (which you can obtain from your TASE broker).
page 3
Q: | What will happen if I fail to vote or I abstain from voting? |
A: | If you do not exercise your vote because you do not submit a properly executed proxy card to Mylan, and do not vote over the Internet or by calling the toll-free number we have provided, in accordance with the instructions contained in this proxy statement in a timely fashion or by failing to attend the AGM to vote in person or fail to instruct your broker, bank, trust company or other nominee how to vote on a non-routine matter (a failure to vote), it will have no effect on the Proposal. If you mark your proxy or voting instructions expressly to abstain or to cast a blank vote for any Proposal, it will also have no effect on such Proposal. If you do not give instructions to your broker, bank, trust company or other nominee, the broker, bank, trust company or other nominee will nevertheless be entitled to vote your ordinary shares in its discretion on routine matters and may give or authorize the giving of a proxy to vote the ordinary shares in its discretion on such matters. For the avoidance of doubt, if a Mylan shareholder returns a properly executed proxy card in a timely fashion without indicating how to vote on one or more of the Proposals (and without indicating expressly to abstain or to cast a blank vote), the Mylan ordinary shares represented by such proxy will count for the purposes of determining the presence of a quorum with respect to such Proposal(s), will be voted in favor of the/each such Proposal in accordance with the recommendation of the Mylan Board, and it will not be considered a failure to vote. |
Q: | What constitutes a quorum? |
A: | At least one-third of the issued Mylan shares must be separately represented at the AGM with respect to a Proposal to constitute a quorum with respect to that Proposal. Abstentions, blank votes and invalid votes will be counted for purposes of determining the presence of a quorum (although they are considered to be votes that were not cast). If you do not give instructions to your broker, bank, trust company or other nominee, the broker, bank, trust company or other nominee will nevertheless be entitled to vote your ordinary shares in its discretion on routine matters and may give or authorize the giving of a proxy to vote the ordinary shares in its discretion on such matters. In such an instance, your shares will be counted for purposes of determining the presence of a quorum with respect to such Proposal. If your broker, bank, trust company or other nominee does not vote your ordinary shares in its discretion on routine matters, your shares will not be counted for purposes of determining the presence of a quorum with respect to such Proposal. Failures to vote (which, as described above, includes instances where you fail to instruct your broker, bank, trust company or other nominee to vote on a non-routine matter) on a Proposal will not be counted for purposes of determining the presence of a quorum with respect to that Proposal. |
Q: | What will happen if I return my proxy card without indicating how to vote? |
A: | If you return your properly executed proxy card in a timely fashion without indicating how to vote on any one or more of the Proposals (and without indicating expressly to abstain or to cast a blank vote), the Mylan ordinary shares represented by such proxy will count for the purposes of determining the presence of a quorum with respect to such Proposal(s), will be voted in favor of each such Proposal in accordance with the recommendation of the Mylan Board, and it will not be considered a failure to vote with respect to such Proposal(s). |
Q: | Can I change my vote after I have returned a proxy card? |
A: | Yes. You can change your vote of your Mylan shares as indicated on your proxy card or revoke your proxy at any time prior to the Cut-Off Time. You can do this by (a) voting again by telephone or the Internet or (b) submitting another properly executed proxy card, dated as of a later date (but prior to the Cut-Off Time), in writing (to be sent to Mylans office address as set forth in the Notice of Annual General Meeting of Shareholders to the attention of Mylans Corporate Secretary). Alternatively, you may give notice of your attendance at the meeting (prior to the Cut-Off Time in the manner described above) and vote in person. |
If your shares are held through and/or in street name by your broker, bank, trust company, other nominee, you should contact your broker, bank, trust company or other nominee to change your vote or revoke your voting instructions.
page 4
Q: | What happens if I transfer my Mylan ordinary shares before the AGM? |
A: | The Record Date for the AGM is earlier than the date of the AGM. If you transfer your Mylan ordinary shares after the Record Date, you will retain your right to attend and vote at the AGM. |
Q: | Where can I find the voting results of the AGM? |
A: | Mylan expects to announce the preliminary voting results at the AGM. In addition, within four business days following certification of the final voting results, Mylan intends to file the final voting results of the AGM with the SEC in a Current Report on Form 8-K. |
Q: | What do I need to do now? |
A: | Carefully read and consider the information contained in this proxy statement and vote your shares either in person or by telephone, the Internet or the use of a proxy card, as described in this proxy statement. |
If you are a Mylan ordinary shareholder who on the Record Date is registered in the Register, in order for your ordinary shares to be represented at the AGM, you can:
| attend the AGM in person; |
| vote through the Internet or by telephone in accordance with the instructions contained in this proxy statement; or |
| indicate on the enclosed proxy card how you would like to vote and return the proxy card in the accompanying pre-addressed postage paid envelope as described in this proxy statement. |
If you are a beneficial owner of Mylan ordinary shares and hold your shares in street name through a bank, broker, trust company or other nominee, the relevant institution will send you instructions describing the procedure for instructing the relevant institution as to how to vote the Mylan ordinary shares you beneficially own.
If you wish to vote the Mylan ordinary shares you beneficially own directly either in person at the AGM or by proxy, you must first obtain a signed legal proxy from the bank, broker, trust company or other nominee through which you beneficially own your Mylan ordinary shares (or if you are a beneficial owner of Mylan ordinary shares traded through the TASE, you instead must obtain a certificate of ownership).
Q: | Who can help answer my questions? |
A: | If you have questions about the Proposals to be voted on at the AGM or if you desire additional copies of this proxy statement or additional proxy cards, you should contact: |
Innisfree M&A Incorporated
501 Madison Avenue
New York, NY 10022
+1 (877) 750-9499 (toll free)
+1 (212) 750-5833 (banks and brokers)
page 5
|
page 6
page 7
page 8
page 9
page 10
Voting Item 1 Appointment of Directors
|
The Mylan Board currently consists of 13 directors, each of whom is either an executive director or a non-executive director pursuant to applicable Dutch law. On April 30, 2017, the Mylan Board voted to reduce the size of the Mylan Board to 11 directors, effective after the annual general meeting. Mr. Leech, Dr. Maroon, and Mr. Piatt will retire from the Mylan Board effective June 22, 2017 and have not been nominated for re-election. On April 30, 2017, the Mylan Board also nominated Sjoerd S. Vollebregt to be elected by shareholders at the annual general meeting to serve as a non-executive director for a term ending immediately after the next annual general meeting held after his election. If each nominated director discussed below is appointed at the annual general meeting, the Mylan Board will consist of 11 directors. Executive directors are responsible for the daily management and operation of the Company and non-executive directors are responsible for overseeing and monitoring the performance of the executive directors.
Consistent with established Dutch law and the Companys articles of association, executive directors and non-executive directors are appointed by the general meeting from a binding nomination proposed by the Mylan Board. The proposed candidate specified in a binding nomination shall be appointed provided that the requisite quorum is present or represented at the general meeting, unless the nomination is overruled by the general meeting (which would result if a majority of at least two-thirds of the votes cast, representing more than half of the issued share capital, vote against the appointment of such director, with abstentions, blank votes and invalid votes not considered votes cast), in which case he or she will not be appointed. In such event, the Mylan Board may propose a new binding nomination to be submitted at a subsequent general meeting. If appointed, each directors term begins at the general meeting at which he or she is appointed and, unless such director resigns or is suspended or dismissed at an earlier date, his or her term of office lapses immediately after the next annual general meeting held after his or her appointment. In accordance with the recommendation of the Companys Governance and Nominating Committee, the Mylan Board has unanimously adopted resolutions to make the following binding nominations:
1. | The Mylan Board has nominated Heather Bresch and Rajiv Malik to serve as executive directors for a term ending immediately after the next annual general meeting held after their appointment. |
2. | The Mylan Board has nominated Wendy Cameron, Hon. Robert J. Cindrich, Robert J. Coury, JoEllen Lyons Dillon, Neil Dimick, Melina Higgins, Mark W. Parrish, Randall L. (Pete) Vanderveen, Ph.D, R.Ph, and Sjoerd S. Vollebregt to serve as non-executive directors for a term ending immediately after the next annual general meeting held after their appointment. |
The Mylan Board and the Governance and Nominating Committee have carefully considered the structure, culture, operation, interactions, collaboration, and performance of the current Mylan Board; the talents, expertise, and contributions of individual directors; the massive growth and creation of shareholder and other stakeholder value under the current Mylan Boards leadership; the continued outstanding performance of the Company; the anticipated future challenges and opportunities facing the Company; and the Mylan Boards ongoing commitment to ensuring the long-term sustainability of the Company to the benefit of shareholders and other stakeholders. Based on these considerations, among others, the Mylan Board recommends a vote FOR the appointment of each director.
Each of the proposed appointments is considered a separate voting item under Dutch law. Information concerning each of the 11 nominated directors is set forth below. Each nominee is currently on the Mylan Board other than Mr. Vollebregt, who is being nominated for the first time this year, and each has consented to act as a director of Mylan if appointed at the annual general meeting. This Voting Item 1 comprises the explanatory notes to the agenda of the annual general meeting as referred to in Section 8.02(d) of Mylans articles of association.
page 11
Name, Age, and Year First Became a Director** |
Principal Occupation and Business Experience; Other Directorships and Qualifications | |
Heather Bresch^ 47 2011
|
Chief Executive Officer
Ms. Bresch has served as Mylans Chief Executive Officer (CEO) since January 1, 2012. Throughout her 25-year career with Mylan, Ms. Bresch has held roles of increasing responsibility in more than 15 functional areas. Prior to becoming CEO, Ms. Bresch was Mylans President commencing in July 2009 and was responsible for the day-to-day operations of the Company. Before that, she served as Mylans Chief Operating Officer and Chief Integration Officer from October 2007 to July 2009, leading the successful integration of two transformational international acquisitions Matrix Laboratories Limited (n/k/a Mylan Laboratories Limited) and Merck KGaAs generics and specialty pharmaceuticals businesses. Under Ms. Breschs leadership, Mylan has continued to expand its portfolio and geographic reach, acquiring Meda, the EPD Business, the female healthcare business of Famy Care Ltd., the non-sterile, topicals-focused business of Renaissance Acquisition Holdings, LLC, and India-based Agila Specialties, a global leader in injectable products and an innovative respiratory technology platform; partnering on portfolios of biologic and insulin products; entering new commercial markets such as China, Southeast Asia, Russia, the Middle East, Mexico, India, Brazil, and Africa; and expanding its leadership in the treatment of HIV/AIDS through the distribution of novel testing devices. During her career, Ms. Bresch has championed initiatives aimed at improving product quality and removing barriers to patient access to medicine. Ms. Breschs qualifications to serve on the Mylan Board include, among others, her extensive industry, policy, and leadership experience and abilities, as well as her strategic vision, judgment and unique and in-depth knowledge about the Company.
| |
Wendy Cameron 57 2002
|
Director and Co-Owner, Cam Land LLC Ms. Cameron has served as Co-Owner and Director of Cam Land LLC, a harness racing business in Washington, Pennsylvania, since January 2003. From 1981 to 1998, she was Vice President, Divisional Sales & Governmental Affairs, Cameron Coca-Cola Bottling Company, Inc. Ms. Cameron served as Chairman of the Washington Hospital Board of Trustees and of the Washington Hospital Executive Committee until she stepped down in 2012. She was a member of the hospitals Board of Trustees from 1997 through 2012 and a member of the Washington Hospital Foundation Board from 1993 through 2012. In addition to being a business owner and having held an executive position with one of the nations largest bottlers for nearly 20 years, Ms. Cameron has invaluable experience and knowledge regarding the business, platforms, strategies, challenges, opportunities, and management of the Company, among other matters. Ms. Camerons qualifications to serve on the Mylan Board include, among others, this experience, as well as her independence, business experience, leadership, and judgment.
|
page 12
Director Nominees (continued)
Name, Age, and Year First Became a Director** |
Principal Occupation and Business Experience; Other Directorships and Qualifications | |
Hon. Robert J. Cindrich 73 2011
|
President, Cindrich Consulting; Counsel, Schnader Harrison Segal & Lewis
Since February 2011, Judge Cindrich has been serving as the President of Cindrich Consulting, LLC, a business and healthcare consulting company that advises clients on corporate governance, compliance, and business strategies, and from October 1, 2013 through January 31, 2014 he served as Interim General Counsel for United States Steel Corporation (NYSE: X), an integrated steel producer of flat-rolled and tubular products. Judge Cindrich joined Schnader Harrison Segal & Lewis (Schnader), a law firm, as legal counsel in April 2013 and took a temporary leave of absence on October 1, 2013 to join United States Steel Corporation as Interim General Counsel, returning to Schnader after his time at United States Steel Corporation. In May 2012, he joined the Board of Directors of Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX), which provides healthcare information technology solutions, where he served until April 2015. From 2011 through 2012, Judge Cindrich served as a senior advisor to the Office of the President of the University of Pittsburgh Medical Center (UPMC), an integrated global health enterprise. From 2004 through 2010, Judge Cindrich was a Senior Vice President and the Chief Legal Officer of UPMC. From 1994 through January 2004, Judge Cindrich served as a judge on the United States District Court for the Western District of Pennsylvania. Prior to that appointment, he was active as an attorney in both government and private practice, including positions as the U.S. Attorney for the Western District of Pennsylvania and as the Allegheny County Assistant Public Defender and Assistant District Attorney. Judge Cindrichs qualifications to serve on the Mylan Board include, among others, his extensive legal and leadership experience and judgment, as well as his independence and in-depth knowledge of the healthcare industry.
|
page 13
Director Nominees (continued)
Name, Age, and Year First Became a Director** |
Principal Occupation and Business Experience; Other Directorships and Qualifications | |
Robert J. Coury 56 2002
|
Chairman
Robert J. Coury is the Chairman of Mylan N.V. Under his visionary leadership, Mylan has transformed from the third largest generics pharmaceutical company in the U.S. into one of the largest pharmaceutical companies in the world in terms of revenue, earning spots in both the S&P 500 and, prior to the Companys reincorporation outside of the U.S. in 2015, the Fortune 500. Mr. Coury was first elected to the Mylan Board in February 2002, having served since 1995 as a strategic advisor to the Company. He became the Mylan Boards Vice Chairman shortly after his election and served as CEO from September 2002 until January 2012, and as Executive Chairman from 2012 until he became Chairman as a director who is not an employee of the Company or Mylan Inc. (a Non-Employee Director, with all such directors being the Non-Employee Directors) in June 2016.
Since 2007, Mr. Coury has led the Company through a series of transactions totaling approximately $25 billion, which transformed Mylan into a global powerhouse within the highly competitive pharmaceutical industry, with a global workforce of over 35,000 and products sold in more than 165 countries. In 2007, Mylan purchased India-based Matrix Laboratories Limited, a major producer of active pharmaceutical ingredients, and the generics and specialty pharmaceuticals business of Europe-based Merck KGaA. Subsequent acquisitions under Mr. Courys leadership further expanded the Company into new therapeutic categories and greatly enhanced its geographic and commercial footprint. In 2010, Mylan acquired Bioniche Pharma, a global injectables business in Ireland; in 2013, Mylan acquired India-based Agila Specialties, a global injectables company; and in 2015, Mylan acquired the EPD Business and Famy Care Ltd.s womens healthcare businesses. Most recently, Mylan acquired Meda, a leading international specialty pharmaceutical company that sells both prescription and over-the-counter products and the non-sterile, topicals-focused business of Renaissance Acquisition Holdings, LLC.
During this period of expansion, the Company built an unmatched, high quality foundation for the future supporting Mylans mission of providing the worlds 7 billion people with access to high quality medicine, and benefiting patients, customers, investors, and other stakeholders. Before becoming Executive Chairman in 2012, Mr. Coury also executed a successful executive leadership transition after cultivating and developing a powerful leadership team. Grooming executive talent from within and recruiting dynamic leaders from outside the Company were both key components of the Companys past, current, and future growth strategies.
Prior to joining Mylan, Mr. Coury was the principal of Coury Consulting, a boutique business advisory firm he formed in 1989, and The Coury Financial Group, a successful financial and estate planning firm, which he founded in 1984.
Mr. Coury is also the founder and president of the Robert J. Coury Family Foundation, which is a charitable organization formed to help support his philanthropic efforts and his mission of giving back. He has served as a member of the University of Southern California Presidents Leadership Council since 2014.
Mr. Courys qualifications to serve on the Mylan Board include, among others, his prior business experience, his in-depth knowledge of the industry, the Company, its businesses, and management, and his leadership experience as the Companys CEO, as well as his judgment, strategic vision, and service and leadership as Vice Chairman and then Chairman of the Mylan Board for more than ten years the most transformational and successful time in the Companys history.
|
page 14
Director Nominees (continued)
Name, Age, and Year First Became a Director** |
Principal Occupation and Business Experience; Other Directorships and Qualifications | |
JoEllen Lyons Dillon 53 2014
|
Executive Vice President, Chief Legal Officer, and Corporate Secretary, The ExOne Company
Ms. Dillon has served as Chief Legal Officer and Corporate Secretary of The ExOne Company (NASDAQ: XONE), a global provider of three-dimensional printing machines, since March 2013, and as Executive Vice President since December 2014. Previously, she was a legal consultant on ExOnes initial public offering. Prior to that experience, Ms. Dillon was a partner with Reed Smith LLP, a law firm, from 2002 until 2011. She had previously been at the law firm Buchanan Ingersoll & Rooney PC from 1988 until 2002, where she became a partner in 1997. Ms. Dillon is a member of the Board of Trustees of the Allegheny District chapter of the National Multiple Sclerosis Society and has previously served as Chair and Audit Committee Chair. Ms. Dillons qualifications to serve on the Mylan Board include, among others, this experience, as well as her independence, judgment, and substantial legal and leadership experience.
| |
Neil Dimick, C.P.A.* 67 2005
|
Retired Executive Vice President and Chief Financial Officer, AmerisourceBergen Corporation
Currently retired, Mr. Dimick previously served as Executive Vice President and Chief Financial Officer of AmerisourceBergen Corporation (NYSE: ABC), a wholesale distributor of pharmaceuticals, from 2001 to 2002. From 1992 to 2001, he was Senior Executive Vice President and Chief Financial Officer of Bergen Brunswig Corporation, a wholesale drug distributor. Prior to that experience, Mr. Dimick served as a partner with Deloitte for eight years. Mr. Dimick also serves on the Boards of Directors of WebMD Health Corp. (NASDAQ: WBMD), Alliance HealthCare Services, Inc. (NASDAQ: AIQ), and Resources Connection, Inc. (NASDAQ: RECN). Mr. Dimick also served on the Boards of Directors of Thoratec Corporation from 2003 to October 2015, at which time it was purchased by St. Jude Medical, Inc. Mr. Dimick has invaluable experience and knowledge regarding the business, platforms, strategies, challenges, opportunities, and management of the Company, among other matters. Mr. Dimicks qualifications to serve on the Mylan Board include, among others, this experience, as well as his independence, substantial industry experience, business and accounting background, and judgment.
|
page 15
Director Nominees (continued)
Name, Age, and Year First Became a Director** |
Principal Occupation and Business Experience; Other Directorships and Qualifications | |
Melina Higgins 49 2013
|
Retired Partner and Managing Director, Goldman Sachs
Currently retired, Ms. Higgins held senior roles of increasing responsibility at The Goldman Sachs Group, Inc. (NYSE: GS) (Goldman Sachs), a global investment banking, securities, and investment management firm, including Partner and Managing Director, during her nearly 20-year career at the firm from 1989 to 1992 and 1994 to 2010. During her tenure at Goldman Sachs, Ms. Higgins served as a member of the Investment Committee of the Principal Investment Area, which oversaw and approved global private equity and private debt investments and was one of the largest alternative asset managers in the world. She also served as head of the Americas and as co-chairperson of the Investment Advisory Committee for the GS Mezzanine Partners funds, which managed over $30 billion of assets and were global leaders in their industry. Ms. Higgins also serves on the Womens Leadership Board of Harvard Universitys John F. Kennedy School of Government. In September 2013, Ms. Higgins joined the Board of Directors of Genworth Financial Inc. (NYSE: GNW), an insurance company. In January 2016, Ms. Higgins became non-executive Chairman of Antares Midco Inc., a private company that provides financing solutions for middle-market, private equity-backed transactions. Ms. Higgins qualifications to serve on the Mylan Board include, among others, her independence, broad experience in finance, and judgment.
| |
Rajiv Malik^ 56 2013
|
President
Mr. Malik has served as Mylans President since January 1, 2012. Previously, Mr. Malik held various senior roles at Mylan, including Executive Vice President and Chief Operating Officer from July 2009 to December 2012, and Head of Global Technical Operations from January 2007 to July 2009. In addition to his oversight of day-to-day operations of the Company as President, Mr. Malik has been instrumental in identifying, evaluating, and executing on significant business development opportunities, expanding and optimizing Mylans product portfolio, and leveraging Mylans global research and development capabilities, among other important contributions. Previously, he served as Chief Executive Officer of Matrix Laboratories Limited (n/k/a Mylan Laboratories Limited) from July 2005 to June 2008. Prior to joining Matrix, he served as Head of Global Development and Registrations for Sandoz GmbH from September 2003 to July 2005. Prior to joining Sandoz GmbH, Mr. Malik was Head of Global Regulatory Affairs and Head of Pharma Research for Ranbaxy from October 1999 to September 2003. Mr. Maliks qualifications to serve on the Mylan Board include, among others, his extensive industry and leadership experience, his understanding of the Asia-Pacific region and other growth markets, his knowledge about the Company, and judgment.
|
page 16
Director Nominees (continued)
Name, Age, and Year First Became a Director** |
Principal Occupation and Business Experience; Other Directorships and Qualifications | |
Mark W. Parrish 61 2009
|
Chief Executive Officer, TridentUSA Health Services
Mr. Parrish has served as Chief Executive Officer of TridentUSA Health Services, a provider of mobile X-ray and laboratory services to the long-term care industry, since 2008 and also served as Chairman from 2008 to 2013. Since January 2013, Mr. Parrish has also served on the Board of Directors of Omnicell, Inc. (NASDAQ: OMCL), a company that specializes in healthcare technology. Mr. Parrish also serves on the Boards of Directors of Silvergate Pharmaceuticals, a private company that develops and commercializes pediatric medications, and GSMS, a private company that specializes in meeting unique labeling and sizing needs for its customers and pharmaceutical packaging, serialization, and distribution. From 2001 to 2007, Mr. Parrish held management roles of increasing responsibility with Cardinal Health Inc. (NYSE: CAH) and its affiliates, including Chief Executive Officer of Healthcare Supply Chain Services for Cardinal Health from 2006 to 2007. Mr. Parrish also serves as President of the International Federation of Pharmaceutical Wholesalers, an association of pharmaceutical wholesalers and pharmaceutical supply chain service companies, and senior adviser to Frazier Healthcare Ventures, a healthcare oriented growth equity firm. Mr. Parrishs qualifications to serve on the Mylan Board include, among others, his independence, extensive industry, business, and leadership experience, knowledge of the healthcare industry, and judgment.
| |
Randall L. (Pete) Vanderveen, Ph.D., R.Ph. 66 2002
|
Professor of Pharmaceutical Policy and Economics, Senior Adviser to the Leonard D. Schaeffer Center of Health Policy and Economics, Director of the Margaret and John Biles Center for Leadership, and Senior Adviser to the Dean for Advancement, School of Pharmacy, University of Southern California
Dr. Vanderveen is currently Professor of Pharmaceutical Policy and Economics, Senior Adviser to the Leonard D. Schaeffer Center of Health Policy and Economics, Director of the Margaret and John Biles Center for Leadership, and Senior Adviser to the Dean for Advancement at the School of Pharmacy, University of Southern California in Los Angeles, California. Dr. Vanderveen previously served as Dean, Professor and John Stauffer Decanal Chair of the USC School of Pharmacy from 2005 to 2015 where he was named Outstanding Pharmacy Dean in the Nation in 2013 by the American Pharmacist Association. From 1998 to 2005, he served as Dean and Professor of Pharmacy of the School of Pharmacy and the Graduate School of Pharmaceutical Sciences at Duquesne University, before which he was Assistant Dean at Oregon State University from 1988 to 1998. Dr. Vanderveen has an extensive pharmaceutical and academic background. In addition, Dr. Vanderveen has invaluable experience and knowledge regarding the business, platforms, strategies, challenges, opportunities, and management of the Company, among other matters. Dr. Vanderveens qualifications to serve on the Mylan Board include, among others, this experience, as well as his independence, pharmaceutical and leadership experience, and judgment.
|
page 17
Director Nominees (continued)
Name, Age, and Year First Became a Director** |
Principal Occupation and Business Experience; Other Directorships and Qualifications | |
Sjoerd S. Vollebregt 62 Nominated for election for the first time in 2017
|
Chairman, Supervisory Board of Heijmans N.V.; Chairman, Advisory Board of Airbus Defence and Space Netherlands B.V.
Mr. Vollebregt has been Chairman of the Supervisory Board of Heijmans N.V., a Euronext Amsterdam listed company that operates in property development, residential building, non-residential building, roads, and civil engineering, since 2015, and Chairman of the Advisory Board of Airbus Defence and Space Netherlands B.V., a subsidiary of Airbus SE, a Euronext Paris listed company, that develops solar arrays, satellite instruments, and structures for launchers, since 2015. Mr. Vollebregt had served as Chairman of the Executive Board of Stork B.V. and its predecessor from 2002 to 2014, which was an Amsterdam Stock Exchange listed industrial group until 2008, consisting of a global provider of knowledge-based maintenance, modification, and asset integrity products and services, food and textile equipment manufacturer, and Chief Executive Officer of Fokker Technologies Group B.V., an aerospace company and a Stork B.V. subsidiary from 2010 to 2014. Previously, Mr. Vollebregt served as a member of the Supervisory Board of TNT Express N.V., an international courier delivery services company, from 2013 to 2016 and has held various other senior positions at Excel plc, Ocean plc, Intexo Holding, and Royal Van Ommeren. Mr. Vollebregts qualifications to serve on the Mylan Board include, among others, this experience as well as his independence, judgment, business and leadership experience, and understanding of and familiarity with managing and serving on the board of directors of other Dutch companies.
|
Ages as of [●], 2017.
^ | Refers to an executive director. All other directors listed above are non-executive directors. |
* | C.P.A. distinctions refer to inactive status. |
** | Includes service as director of Mylan Inc. and Mylan N.V. Each director listed above, other than Mr. Vollebregt, was a director of Mylan Inc. on February 27, 2015, the date on which Mylan N.V. completed the EPD Transaction, and became a director of Mylan N.V. on such date in connection with the EPD Transaction. |
THE MYLAN BOARD UNANIMOUSLY RECOMMENDS A VOTE FOR THE APPOINTMENT OF MS. BRESCH AND MR. MALIK AS EXECUTIVE DIRECTORS AND EACH OF THE OTHER NOMINEES DISCUSSED ABOVE AS NON-EXECUTIVE DIRECTORS.
page 18
The table below provides the current membership and 2016 meeting information for the noted Mylan Board committees of Mylan.
Director
|
Audit
|
Compensation
|
Compliance
|
Executive
|
Finance
|
Governance
|
Science &
| |||||||
Heather Bresch |
X | |||||||||||||
Wendy Cameron |
C | X | ||||||||||||
Hon. Robert J. Cindrich |
X | X | X | |||||||||||
Robert J. Coury |
C | |||||||||||||
JoEllen Lyons Dillon(1) |
X | X | X | |||||||||||
Neil Dimick(1) |
C | X | X | X | ||||||||||
Melina Higgins |
X | C | ||||||||||||
Douglas J. Leech(2) |
X | X | C | |||||||||||
Rajiv Malik |
X | |||||||||||||
Joseph C. Maroon, M.D.(2) |
X | X | C | |||||||||||
Mark W. Parrish |
X | C | X | |||||||||||
Rodney L. Piatt(2) |
X | X | X | X | ||||||||||
Randall L. (Pete) Vanderveen, Ph.D., R.Ph. |
X | X | ||||||||||||
Meetings during 2016 |
4 | 6 | 4 | 2 | 4 | 4 | 3 |
(1) | Ms. Dillon joined the Audit Committee and Governance and Nominating Committee on June 24, 2016. Mr. Dimick joined the Governance and Nominating Committee on June 24, 2016 and served on the Finance Committee until June 24, 2016. |
(2) | Mr. Leech, Dr. Maroon and Mr. Piatt are not nominated for election at the annual general meeting. |
C = Chair
X = Member
Copies of the committee charters of Mylan are available on Mylans website at http://www.mylan.com/company/corporate-governance or in print to shareholders upon request, addressed to Mylan N.V.s Corporate Secretary at Building 4, Trident Place, Mosquito Way, Hatfield, Hertfordshire, AL10 9UL, England.
page 19
page 20
page 21
page 22
page 23
page 24
Non-Employee Director Compensation for 2016
The following table sets forth information concerning the compensation earned by the Non-Employee Directors, other than Mr. Coury, for 2016. Directors who are employees of Mylan Inc. do not receive any consideration for their service on the Mylan Board. A discussion of the elements of Non-Employee Director compensation follows the table.
Name(1) |
Fees Earned or Paid in Cash ($) |
RSUs ($)(2) | Option Awards ($)(2) |
All Other Compensation ($) |
Total ($) | |||||
Wendy Cameron |
132,000 | 165,045 | 50,017 | | 347,062 | |||||
Hon. Robert J. Cindrich |
120,000 | 165,045 | 50,017 | | 335,062 | |||||
JoEllen Lyons Dillon |
119,500 | 165,045 | 50,017 | | 334,562 | |||||
Neil Dimick |
177,000 | 165,045 | 50,017 | | 392,062 | |||||
Melina Higgins |
132,000 | 165,045 | 50,017 | | 347,062 | |||||
Douglas J. Leech |
125,000 | 165,045 | 50,017 | | 340,062 | |||||
Joseph C. Maroon, M.D |
127,000 | 165,045 | 50,017 | | 342,062 | |||||
Mark W. Parrish |
145,000 | 165,045 | 50,017 | | 360,062 | |||||
Rodney L. Piatt |
212,000 | 165,045 | 50,017 | | 427,062 | |||||
Randall L. (Pete) Vanderveen, Ph.D., R.Ph. |
113,000 | 165,045 | 50,017 | | 328,062 |
(1) | In the case of Mr. Coury, the amounts he received in connection with his service as a Non-Employee Director following his retirement as an executive officer and transition to Chairman are described in the Summary Compensation Table for 2016 below and the section entitled Chairman Transition, beginning on page [●] of this Proxy Statement. |
(2) | Represents the grant date fair value of the specific award granted to the Non-Employee Director. Option awards and restricted stock unit (RSU) awards granted in 2016 vested on February 17, 2017. For information regarding assumptions used in determining the amounts reflected in the table above, please refer to Note 11 to the Companys Consolidated Financial Statements contained in the Form 10-K for the year ended December 31, 2016. The aggregate number of ordinary shares subject to stock options held by the Non-Employee Directors listed in the table as of December 31, 2016 were as follows: Ms. Cameron, 8,365; Judge Cindrich, 8,365; Ms. Dillon, 8,365; Mr. Dimick, 8,365; Ms. Higgins, 14,988; Mr. Leech, 8,365; Dr. Maroon, 8,365; Mr. Parrish, 8,365; Mr. Piatt, 84,916; and Dr. Vanderveen, 8,365. The number of unvested RSUs held by each of the Non-Employee Directors listed in the table, as of December 31, 2016, was 3,567. The number of ordinary shares subject to stock options and the number of unvested RSUs and restricted ordinary shares held by Mr. Coury as of December 31, 2016 are provided in the Outstanding Equity Awards at the End of 2016 Table on page [●] of this Proxy Statement. |
page 25
page 26
Security Ownership of Directors, Nominees, and Executive Officers
The following table sets forth information regarding the beneficial ownership of ordinary shares of Mylan N.V. as of [●], 2017 by (i) Mylan N.V.s directors, nominees, and named executive officers (NEOs), and (ii) all directors, nominees, and executive officers of Mylan N.V. as a group (based on [●] ordinary shares of Mylan N.V. outstanding as of such date). For purposes of this table, and in accordance with the rules of the SEC, shares are considered beneficially owned if the person, directly or indirectly, has sole or shared voting or investment power over such shares. A person is also considered to beneficially own shares that he or she has the right to acquire within 60 days of [●], 2017. To Mylan N.V.s knowledge, the persons in the following table have sole voting and investment power, either directly or through one or more entities controlled by such person, with respect to all of the shares shown as beneficially owned by them, unless otherwise indicated in the footnotes below.
Name of Beneficial Owner |
Amount and Nature of Beneficial Ownership |
Options Exercisable and Restricted Shares Vesting within 60 days |
Percent of Class | |||||||
Heather Bresch |
842,927 | (1)(6) | 165,705 | * | ||||||
Wendy Cameron |
70,579 | 8,365 | * | |||||||
Hon. Robert J. Cindrich |
16,951 | 8,365 | * | |||||||
Robert J. Coury |
1,466,279 | (2)(6) | 231,074 | * | ||||||
JoEllen Lyons Dillon |
7,511 | 8,365 | * | |||||||
Neil Dimick |
42,489 | 8,365 | * | |||||||
Melina Higgins |
79,439 | (3) | 14,988 | * | ||||||
Douglas J. Leech** |
46,282 | 8,365 | * | |||||||
Rajiv Malik |
824,855 | (6) | 78,870 | * | ||||||
Joseph C. Maroon, M.D.** |
25,603 | 8,365 | * | |||||||
Anthony Mauro |
156,227 | (4)(6) | 44,217 | * | ||||||
Kenneth S. Parks |
1,368 | 5,517 | * | |||||||
Mark W. Parrish |
35,267 | 8,365 | * | |||||||
Rodney L. Piatt** |
39,960 | 84,916 | * | |||||||
John D. Sheehan, C.P.A.(5) |
126,220 | 38,038 | * | |||||||
Randall L. (Pete) Vanderveen, Ph.D., R.Ph. |
39,689 | 8,365 | * | |||||||
Sjoerd S. Vollebregt(7) |
0 | 0 | * | |||||||
All directors, nominees, and executive officers as a group (17 persons, including Daniel M. Gallagher(8) but not including Mr. Sheehan(5)) |
3,695,426 | (6)(9) | 692,207 | * |
* | Less than 1%. |
** | Mr. Leech, Dr. Maroon, and Mr. Piatt are not nominated for election at the annual general meeting. |
(1) | Includes 1,157 shares held in Ms. Breschs 401(k) account and 200,000 shares held in a grantor retained annuity trust of which Ms. Bresch is the sole trustee. |
(2) | Includes 1,000,000 shares held in a grantor retained annuity trust of which Mr. Coury is the sole trustee. |
(3) | Includes 74,000 shares held by Ms. Higgins spouse. |
(4) | Includes 5,574 shares held in Mr. Mauros 401(k) account. |
(5) | Mr. Sheehan departed from Mylan effective April 1, 2016. |
(6) | Includes restricted ordinary shares issued on June 10, 2015 upon conversion of stock appreciation rights (SARs) pursuant to the terms of Mylans One-Time Special Performance-Based Incentive Program (as defined below) implemented in 2014. The restricted ordinary shares remain subject to forfeiture and additional vesting conditions, including achievement of adjusted EPS of $6.00 and continued service, and the other terms and conditions of the program. |
(7) | Mr. Vollebregt is nominated for election to the Mylan Board for the first time in 2017. |
(8) | More information on Mr. Gallagher can be found in the Executive Officers section of this Proxy Statement. |
(9) | Includes 6,731 shares held in the executive officers 401(k) accounts. |
page 27
Security Ownership of Certain Beneficial Owners
The following table lists the names and addresses of the shareholders known to management to own beneficially more than five percent of the ordinary shares of Mylan N.V. as of [●], 2017 (based on [●] ordinary shares of Mylan N.V. outstanding as of such date):
Name and Address of Beneficial Owner |
Amount and Nature of Beneficial Ownership |
Percent of Class | ||
Wellington Management Company LLP and affiliates, 280 Congress Street, Boston, MA 02210 |
45,207,406(1) | [●]% | ||
BlackRock, Inc., |
39,714,103(2) | [●]% | ||
Vanguard Specialized Funds Vanguard Heath Care Fund |
30,084,537(3) | [●]% | ||
The Vanguard Group, 100 Vanguard Blvd., Malvern, PA 19355 |
28,258,025(4) | [●]% |
(1) | Based on Schedule 13G/A filed by Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP and Wellington Management Company LLP with the SEC on February 9, 2017, Wellington Management Group LLP has sole voting power over 0 shares, shared voting power over 9,212,021 shares, sole dispositive power over 0 shares, and shared dispositive power over 45,207,406 shares; Wellington Group Holdings LLP has sole voting power over 0 shares, shared voting power over 9,212,021 shares, sole dispositive power over 0 shares, and shared dispositive power over 45,207,406 shares; Wellington Investment Advisors Holdings LLP has sole voting power over 0 shares, shared voting power over 9,212,021 shares, sole dispositive power over 0 shares, and shared dispositive power over 45,207,406 shares; and Wellington Management Company LLP has sole voting power over 0 shares, shared voting power over 7,160,105 shares, sole dispositive power over 0 shares, and shared dispositive power over 42,107,636 shares. Based on the Schedule 13G/A, the securities as to which the Schedule 13G/A was filed are owned of record by clients of one or more investment advisers identified therein directly or indirectly owned by Wellington Management Group LLP. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. No such client is known to have such right or power with respect to more than five percent of this class of securities, except for Vanguard Health Care Fund. |
(2) | Based on Schedule 13G/A filed by BlackRock, Inc. with the SEC on January 25, 2017, BlackRock, Inc. has sole voting power over 35,999,853 shares, shared voting power over 0 shares, sole dispositive power over 39,714,103 shares, and shared dispositive power over 0 shares. |
(3) | Based on Schedule 13G filed by Vanguard Specialized Funds Vanguard Health Care Fund 23-2439149 on February 13, 2017, Vanguard Specialized Funds Vanguard Health Care Fund 23-2439149 has sole voting power over 30,084,537 shares, shared voting power over 0 shares, sole dispositive power over 0 shares, and shared dispositive power over 0 shares. |
(4) | Based on Schedule 13G filed by The Vanguard Group with the SEC on February 10, 2017, The Vanguard Group has sole voting power over 715,299 shares, shared voting power over 76,324 shares, sole dispositive power over 27,487,177 shares, and shared dispositive power over 770,848 shares. |
Section 16(a) Beneficial Ownership Reporting Compliance
Section 16(a) of the Securities Exchange Act of 1934, as amended (the Exchange Act), requires all directors and certain executive officers and persons who own more than 10% of a registered class of Mylans equity securities to file with the SEC within specified due dates reports of ownership and reports of changes of ownership of Mylan ordinary shares and our other equity securities. These persons are required by SEC regulations to furnish us with copies of all Section 16(a) reports they file. Based on reports and written representations furnished to us by these persons, we believe that all Mylan directors and relevant executive officers complied with these filing requirements during 2016.
page 28
The names, ages, and positions of Mylans executive officers as of [●], 2017, are as follows:
Heather Bresch |
47 | Chief Executive Officer (principal executive officer) | ||
Daniel M. Gallagher |
44 | Chief Legal Officer | ||
Rajiv Malik |
56 | President | ||
Anthony Mauro |
44 | Chief Commercial Officer | ||
Kenneth S. Parks |
53 | Chief Financial Officer (principal financial officer) |
page 29
page 30
Voting Item 2 Adoption of Dutch Annual Accounts for Fiscal Year 2016
|
At the annual general meeting, shareholders will be asked to adopt the Companys Dutch statutory annual accounts for the fiscal year ended December 31, 2016, which are prepared in accordance with International Financial Reporting Standards as adopted by the European Union (IFRS).
As a public limited liability company incorporated under the laws of the Netherlands, Mylan is required by Dutch law to prepare the Dutch statutory annual accounts and submit them to shareholders for adoption. The Companys Dutch statutory annual accounts are different from the consolidated financial statements contained in our annual report on Form 10-K for the year ended December 31, 2016 that were prepared in accordance with U.S. GAAP and filed with the SEC.
A copy of the Dutch statutory annual accounts is available free of charge on our website at http://www.mylan.com/en/company/corporate-governance and at our office address at Building 4, Trident Place, Mosquito Way, Hatfield, Hertfordshire, AL10 9UL England.
A representative of Deloitte Accountants B.V. is expected to be present at the annual general meeting and will be available to respond to appropriate questions from shareholders, and will be given an opportunity to make a statement if he or she desires to do so.
THE MYLAN BOARD UNANIMOUSLY RECOMMENDS A VOTE FOR THE ADOPTION OF OUR DUTCH STATUTORY ANNUAL ACCOUNTS FOR FISCAL YEAR 2016.
page 31
Voting Item 3 Ratification of the Selection of Deloitte & Touche LLP as the Companys Independent Registered Public Accounting Firm for Fiscal Year 2017
|
page 32
Report of the Audit Committee of the Mylan Board
The following Report of the Audit Committee of the Mylan Board does not constitute soliciting material and shall not be deemed filed or incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent the Company specifically incorporates such information by reference.
April 30, 2017
The Audit Committee is currently comprised of five directors, each of whom is independent as required by and as defined in the audit committee independence standards of the SEC and the applicable NASDAQ listing standards. The Audit Committee operates under a written charter adopted by the Board, a copy of which is available on the Companys website at mylan.com/company/corporate-policy.
Management is responsible for the preparation and integrity of the Companys financial statements. Management is also responsible for implementing and maintaining appropriate accounting and financial reporting policies, procedures, and internal controls designed to ensure compliance with applicable accounting standards and laws and regulations. The independent registered public accounting firm (the independent auditor) is responsible for auditing and reviewing the Companys financial statements and auditing the Companys internal control over financial reporting, in accordance with standards of the Public Company Accounting Oversight Board (PCAOB), and to issue their reports thereon. One of the Audit Committees responsibilities is to oversee these processes.
In this context, the Audit Committee met a total of four times in 2016, and has reviewed and discussed with management, including Mylans internal auditor, and with the independent auditor Mylans audited consolidated financial statements and its internal control over financial reporting. These discussions covered the quality, as well as the acceptability, of Mylans financial reporting practices and the completeness and clarity of the related financial disclosures as well as the effectiveness of Mylans internal control over financial reporting and its disclosure controls and procedures. Management represented to the Audit Committee that Mylans consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States, and the Audit Committee has reviewed and discussed the consolidated financial statements with management and the independent auditor. The Audit Committee discussed with the independent auditor the matters required to be discussed by Auditing Standard No. 16 (as codified, AS 1301).
Mylans independent auditor also provided to the Audit Committee the written disclosures and letter required by the applicable requirements of the PCAOBs Rule 3526 regarding the independent auditors communications with the Audit Committee concerning the independent auditors independence, and the Audit Committee discussed these matters with the independent auditor. The Audit Committee has also considered whether the independent auditors provision of non-audit services to Mylan is compatible with the firms independence. Deloitte & Touche LLP, Mylans independent auditor, stated in the written disclosures that in their judgment they are, in fact, independent. The Audit Committee concurred in that judgment of independence.
Based upon the review and discussions referred to above, the Audit Committee recommended to the Board that the audited consolidated financial statements be included in Mylans Annual Report on Form 10-K for 2016, which was filed with the Securities and Exchange Commission.
BY THE AUDIT COMMITTEE:
Neil Dimick, C.P.A., Chairman
JoEllen Lyons Dillon
Melina Higgins
Douglas J. Leech, C.P.A.
Rodney L. Piatt, C.P.A.
page 33
Voting Item 4 Instruction to Deloitte Accountants B.V. for the Audit of the Companys Dutch Statutory Annual Accounts for Fiscal Year 2017
|
Pursuant to Dutch law, the general meeting is authorized to appoint an auditor to audit the Companys Dutch statutory annual accounts, which are presented pursuant to IFRS. Based on the recommendation of the Audit Committee of the Mylan Board, the Mylan Board proposes to the general meeting that Deloitte Accountants B.V. be instructed to serve as the auditor who will audit our Dutch statutory annual accounts as required by Dutch law for the year ending December 31, 2017.
THE MYLAN BOARD UNANIMOUSLY RECOMMENDS A VOTE FOR THE INSTRUCTION TO DELOITTE ACCOUNTANTS B.V. FOR THE AUDIT OF THE COMPANYS DUTCH STATUTORY ANNUAL ACCOUNTS FOR FISCAL YEAR 2017.
page 34
Executive Compensation for 2016
|
Compensation Discussion and Analysis
This Compensation Discussion and Analysis (CD&A) describes the compensation of the following NEOs for 2016.
Name |
Position | |
Heather Bresch |
Chief Executive Officer | |
Kenneth S. Parks |
Chief Financial Officer | |
Rajiv Malik |
President | |
Anthony Mauro |
Chief Commercial Officer | |
John D. Sheehan, CPA(1) |
Former Executive Vice President and Chief Financial Officer | |
Robert J. Coury(2) |
Former Executive Chairman, currently Chairman of the Mylan Board as a Non-Employee Director |
(1) | Mr. Sheehan departed Mylan effective April 1, 2016. |
(2) | In June 2016, the Mylan Board, in another step toward further ensuring strong and stable long-term leadership of the Company, as discussed in further detail below, unanimously approved Mr. Courys retirement and transition from Executive Chairman to the role of Chairman of the Mylan Board as a Non-Employee Director. This change was effective as of the close of the 2016 AGM. |
Leading Global Pharmaceutical Company Providing Access to High Quality Medicine
Company Mission |
At Mylan, we are committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we:
Innovate to satisfy unmet needs;
Make reliability and service excellence a habit;
Do whats right, not whats easy; and
Impact the future through passionate global leadership.
| |
Business Overview |
Global Reach:
One of the largest pharmaceutical companies in the world today in terms of revenue
Develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products, as well as active pharmaceutical ingredients (API)
One of the industrys broadest product portfolios, including more than 7,500 marketed products globally; supplies antiretroviral therapies to approximately 50% of people being treated for HIV/AIDS in the developing world |
page 35
Balanced and diversified global commercial footprint with products sold in more than 165 countries and territories
Operates a global, high quality, vertically-integrated manufacturing platform with 50 manufacturing sites worldwide
Strong and innovative R&D network that has consistently delivered a robust product pipeline, including complex products such as injectables, respiratory products, insulin analogs, and biosimilars
A talented global workforce of more than 35,000 employees as of December 31, 2016
| ||
U.S. Business Overview:
Mylan holds a top two ranking within the U.S. generics prescription market in terms of both sales and prescriptions dispensed
More than 635 brand, generic, and OTC products marketed in the U.S.
Our medicines filled one of every 13 prescriptions in the U.S. more than Pfizer, GlaxoSmithKline, Johnson & Johnson, AstraZeneca, Merck, Sanofi, and Eli Lilly combined representing more than 22 billion doses at an average price of just 25 cents per dose
Nearly 80% of Mylans products sold in the U.S. are manufactured in the U.S.
A talented workforce of approximately 7,000 located in the U.S. |
page 36
Over 70 Years of Combined Service and Experience Among a Leadership Team that has Delivered Sustained Value
Our Chairman, Mr. Coury, joined the Mylan Board and became CEO and Vice Chairman in 2002 and CEO and Chairman in 2009, transitioning to the role of Executive Chairman in 2012, a position he held through June 24, 2016, when he became Chairman as a Non-Employee Director.
Our CEO, Ms. Bresch, has served Mylan for 25 years in roles of increasing responsibility in more than 15 functional areas.
Our President, Mr. Malik, has served Mylan for approximately ten years since joining Mylan in 2007 through the acquisition of Matrix Laboratories, one of the worlds largest suppliers of API (and prior to that had another 20 years of experience in the pharmaceutical industry).
Our Chief Commercial Officer, Mr. Mauro, has been with Mylan for over 20 years, in roles of increasing responsibility in our commercial businesses.
|
page 37
Performance Against 2016 Annual Incentive Plan Metrics
* | The adjusted EPS amount is derived from Mylans audited financial statements in the same manner as Mylan publicly reports adjusted EPS (which for 2016 is reconciled to the most directly comparable U.S. GAAP measure in Appendix A), but for annual incentive plan purposes is measured on a constant currency basis. Adjusted free cash flow is derived from Mylans audited financial statements in the same manner as Mylan publicly reports adjusted free cash flow (which for 2016 is reconciled to the most directly comparable U.S. GAAP measure in Appendix A). |
Percentages reflect total Net Third Party Sales
page 38
As our customers continue to consolidate and global demand for medicines increases, Mylan is uniquely positioned to meet these needs through our scale, global supply chain, and commitment to driving access. |
We believe there simply is no other company that combines our unique operating platform, tremendous work ethic, willingness to challenge the status quo, and desire to champion the cause of better health for the worlds 7 billion people in order to serve the interests of all stakeholders. |
|||||
We continue to leverage our differentiated, global operating platform. This vertically-integrated platform includes 50 manufacturing sites around the world, with extensive capabilities and the capacity to produce approximately 80 billion oral solid doses, 4,800 kiloliters of APIs, 500 million injectable units, and 1.5 billion complex-product units annually to high quality standards and with the efficiency to manage costs. |
We use our strong commercial presence, with critical mass across the generics, brand, and OTC channels, to keep expanding and delivering value for our customers. We have one of the industrys broadest and most diverse portfolios, with more than 7,500 marketed products. Our global sales force of more than 5,000 calls on approximately 60,000 customers worldwide. Through ONE Mylan (a term that describes our expansive, diversified, and integrated commercial and operational platform), we have opportunities to be the partner of choice to continue to drive revenue growth. | ||||||
We are making significant ongoing investments in our future organic growth. We invested approximately $3 billion in R&D in the last five years, including approximately $827 million in the last year alone. As a result, we have more than 1,800 additional new product submissions pending regulatory approval, and more than 6,000 more submissions planned. These include complex products such as injectables and respiratory products as well as insulin analogs and biosimilars, where we have one of the industrys largest and broadest portfolios. |
| We will continue to pursue business-development transactions that fit strategically and culturally into Mylan and will add value while ensuring ongoing financial flexibility with a strong balance sheet and maintaining our commitment to our investment grade credit rating. |
| We have a strong track record of delivering exceptional shareholder returns, and we will work to maintain this exceptional record. |
| We are putting our commitment to global social responsibility to action by championing Better Health for a Better World. |
page 39
Robust R&D Investment and Product Pipeline
~$3B of cumulative investment, 2012 2016
* | QuintilesIMS, a leading provider of technology and analytics to the healthcare industry. |
Global Integrated R&D Network
page 40
Pay Element |
Form | 2016 Metrics | 2016 Performance / Shareholder Alignment Link | |||
Salary |
Cash |
N/A |
Base compensation set competitively to attract and retain executives
| |||
Annual Incentive Compensation |
Cash |
Adjusted EPS |
Earnings are expected to have a direct relationship to the price of Mylans ordinary shares
| |||
Global regulatory submissions |
Approval and commercialization of new products yield new revenue sources that are essential for Mylan to remain competitive, and as such are fundamental to our short- and long-term growth strategy
| |||||
Adjusted free cash flow |
Captures the potential impact of all types of business transactions on the generation of adjusted operating cash flow
| |||||
Long-Term Incentive Compensation |
Stock Options |
Stock price |
Provides value only if stock price rises from the grant date | |||
Restricted Stock Units (RSUs)
|
Stock price |
Realized value depends on continued employment and absolute stock performance over time
| ||||
PRSUs |
ROIC |
Focuses executives on earning an appropriate return on investments
| ||||
Relative total shareholder return (TSR)
|
Incentivizes executives to deliver superior shareholder returns as compared to competitors
|
2016 Pay Mix
page 41
page 42
Alignment of CEO Realizable Pay* with TSR Performance
* | Realizable pay includes cumulative salary and annual incentives paid for the most recent three years, plus current value (as of December 31, 2016) of options (intrinsic value) and time-based restricted stock/units granted during the most recent three years, plus the value (as of December 31, 2016) of performance-based long-term incentive awards earned during the most recent three years, plus change in pension value and all other compensation for the most recent three years. TSR data is from the S&P Research Insight database. Peer companies in this chart reflect the 2016 peer companies listed on page [●] of this Proxy Statement, excluding Teva Pharmaceutical Industries Ltd., for whom sufficient information was not publicly available. Note that Perrigo Company plc three-year realizable pay excludes the most recent 6-month stub year, and Mylans realizable pay excludes awards granted in connection with the One-Time Special Performance-Based Incentive Program (as defined below), since these performance awards are still subject to performance-based criteria. |
page 43
Changes Made to Compensation Program Based on Board Analysis and/or Shareholder Feedback |
Impact of Change | |||
In connection with Mr. Courys transition from Executive Chairman to Chairman as a Non-Employee Director, his total annualized compensation package is lower than previous levels
¡ This years Summary Compensation Table and accompanying tables within this Proxy Statement show compensation previously granted to Mr. Coury that became payable as a result of this transition or that will be earned in the future |
Mr. Coury will continue to provide the overall strategic leadership of the Company
80% of the compensation Mr. Coury will receive as Chairman as a Non-Employee Director is in the form of shareholder aligned RSUs that vest over five years and therefore promote his continued strategic leadership | |||
Removed automatic accelerated vesting of stock option, RSU, and PRSU awards for eligible executives upon an individual satisfying retirement-eligibility criteria (55 years of age with ten+ years of service) |
Further promotes the goal of ensuring stable leadership and executive retention
Ms. Bresch and Mr. Malik have voluntarily waived their right to this provision for previously granted RSUs and PRSUs | |||
Intention to rely on a simplified mix of base salary, annual cash-based incentive awards, and long-term incentive awards over the next few years |
Historically-important but complex compensation components are being phased out
New NEOs do not have Retirement Benefit Agreements (RBAs) | |||
Reduced expatriate benefits payable to our President, Mr. Malik |
Pursuant to Mr. Maliks expatriate assignment to the U.S. from India, Mr. Malik was responsible for taxes equal to those he would have been obligated to pay if he maintained his principal work location and residence in India, while Mylan was responsible for all additional taxes
Beginning in 2016, Mr. Malik no longer receives a tax equalization benefit for long-term incentive awards | |||
Introduced a U.S. GAAP revenue metric for 2017 annual incentive compensation |
Incentivizes management to focus on top-line growth, essential to Mylans ongoing value creation and consistent with our long-term growth strategy
Affirms Mylans commitment to maintaining a tight link between compensation and objective performance results | |||
Increased transparency on our pay philosophy and efforts to more closely align pay with performance |
Additional clarity for shareholders on the items that we believe best incentivize and help retain critical senior leaders
Additional line-of-sight on how we compensate management on a long-term basis for outstanding relative performance |
page 44
March 31, 2006 |
December 31, 2016 | |||
Workforce |
~3,000 | >35,000 | ||
R&D Staff |
~300 | ~3,000 | ||
Manufacturing |
5 Sites | 50 Sites | ||
Portfolio |
~150 Products | >7,500 Marketed Products | ||
Geography |
Domestic (U.S.) Only | >165 Countries and Territories |
page 45
page 46
2016 Pay Mix
NEO |
Position |
2015 |
2016* |
Change in | ||||||
Heather Bresch |
Chief Executive Officer | $1,300,000 | $1,300,000 | 0% | ||||||
Kenneth S. Parks |
Chief Financial Officer | N/A | 600,000 | | ||||||
Rajiv Malik |
President | 1,000,000 | 1,000,000 | 0% | ||||||
Anthony Mauro |
Chief Commercial Officer | 625,000 | 700,000 | 12% |
* | Prior to his departure from Mylan on April 1, 2016, Mr. Sheehan received an annual base salary of $650,000. Prior to his transition to Chairman as a Non-Employee Director, Mr. Coury received an annual base salary of $1,350,000. |
page 47
Adjusted EPS |
Earnings are expected to have a direct relationship to the price of Mylans ordinary shares
| |
Global Regulatory Submissions |
Approval and commercialization of new products yield new revenue sources that are essential for Mylan to remain competitive, and as such are fundamental to our short- and long-term growth strategy
| |
Adjusted Free Cash Flow |
Captures the potential impact of all types of business transactions on the generation of adjusted operating cash flow, and strengthens our balance sheet
|
| Setting Challenging Targets Based on Past Performance Results and Future Expectations. For 2016, the Compensation Committee set adjusted EPS and adjusted free cash flow targets at 13% and 8% increases, respectively over prior year performance. The Compensation Committee set the global regulatory submissions target based on forecasts for submissions for the year. The following tables show the 2016 threshold, target, and maximum goals and the relative weightings of each metric: |
Goal |
Weighting |
Threshold |
Target |
Maximum |
||||||||||||||||||||||||||||||||||||
Adjusted EPS |
50 | % | $ | 4.85 | $ | 5.00 | $ | 5.15 | ||||||||||||||||||||||||||||||||
Global regulatory submissions |
25 | % | 120 | 135 | 150 | |||||||||||||||||||||||||||||||||||
Adjusted free cash flow ($ in millions) |
25 | % | $ | 1,800 | $ | 2,000 | $ | 2,200 |
No annual incentives are paid if threshold performance is not achieved. Furthermore, the Compensation Committee has committed to not using its discretion to upwardly adjust annual incentive award amounts generated by the performance metrics.
page 48
| Potential Opportunities Subject to Performance. Set forth below are the 2016 threshold, target, and maximum award opportunities for the NEOs who are currently executive officers: |
NEO* |
Position | Threshold (% of Salary) |
Target (% of Salary) |
Maximum (% of Salary) |
||||||||||||||||||||||||||||
Heather Bresch |
Chief Executive Officer |
75.0% | 150% | 300% | ||||||||||||||||||||||||||||
Kenneth S. Parks |
Chief Financial Officer |
50.0% | 100% | 200% | ||||||||||||||||||||||||||||
Rajiv Malik |
President |
62.5% | 125% | 250% | ||||||||||||||||||||||||||||
Anthony Mauro |
Chief Commercial Officer |
57.5% | 115% | 230% |
* | As a result of his announced departure from Mylan, Mr. Sheehan was not granted an annual incentive award for 2016. As a result of his transition to Chairman as a Non-Employee Director, Mr. Coury received only a pro-rated annual incentive award for 2016, the value of which is included in the column entitled Non-Equity Incentive Plan Compensation in the Summary Compensation Table on page [●] of this Proxy Statement. |
| Annual Incentive Payouts. The annual incentives earned for 2016 were determined based on the annual performance criteria, and the relative weightings and Company results set forth in the table below. The Company achieved threshold performance with respect to the adjusted EPS metric, exceeded maximum performance on the global submissions metric, and exceeded target performance on the adjusted free cash flow metric in 2016. As a result, the NEOs received payouts of annual incentive awards for 2016 at 116.75% of target. |
Goal* |
Weighting |
2016 Target |
2016 Actual |
Weighted |
||||||||||||||||||||||||||||||||||||||||||||||
Adjusted EPS |
50 | % | $ | 5.00 | $ | 4.85 | Threshold | 25.00% | ||||||||||||||||||||||||||||||||||||||||||
Global regulatory submissions |
25 | % | 135 | 155 | Above maximum | 50.00% | ||||||||||||||||||||||||||||||||||||||||||||
Adjusted free cash flow ($ in millions) |
25 | % | $ | 2,000 | $ | 2,134 | Above target | 41.75% | ||||||||||||||||||||||||||||||||||||||||||
2016 Company Performance Score |
116.75% |
* | The adjusted EPS amount is derived from Mylans audited financial statements in the same manner as Mylan publicly reports adjusted EPS (which for 2016 is reconciled to the most directly comparable U.S. GAAP measure in Appendix A), but for annual incentive plan purposes is measured on a constant currency basis. Adjusted free cash flow is derived from Mylans audited financial statements in the same manner as Mylan publicly reports adjusted free cash flow (which for 2016 is reconciled to the most directly comparable U.S. GAAP measure in Appendix A). |
The annual incentive compensation earned by each of the NEOs for 2016 is set forth in the column entitled Non-Equity Incentive Plan Compensation in the Summary Compensation Table on page [●] of this Proxy Statement.
Long-Term Incentive Compensation
The Compensation Committee believes that the value of long-term incentives should be directly related to the performance of Mylans ordinary shares, as well as other measures associated with the growth and success of Mylan.
| Long-Term Incentive Structure. For 2016, long-term incentive awards were granted to our NEOs in the form of stock options, time-based RSUs, and PRSUs. |
page 49
The mix of awards, detailed below, provides recipients with a combination of incentive opportunities, aligns our executives with shareholders, and each vehicle has its own risk-reward profile and provides a unique benefit. The Compensation Committee believes that maintaining a higher percentage of the total long-term incentive award that is specifically performance-based further supports alignment between the Companys performance, shareholder interests, and executive compensation.
Vehicle |
Approx. Weight for all NEOs* Except Mr. Parks |
Weight for Mr. Parks |
Incentive Opportunity | |||||||||||||||||||
Stock Options |
17% | 20% | Stock options provide value only if Mylans ordinary share price rises from the grant date
| |||||||||||||||||||
RSUs |
31% | 20% | RSU value increases/decreases with ordinary share price performance, and provides a strong retention value
| |||||||||||||||||||
PRSUs |
52% | 60% | PRSUs provide value based on Mylans ROIC and relative TSR performance, strongly linking payouts with long-term value creation
|
* | Mr. Sheehan did not receive a long-term incentive award in 2016 due to his announced departure from Mylan. |
| Stock options. Stock options are granted with an exercise price equal to the closing price of Mylans ordinary shares on the date of grant. They vest in three equal installments, generally provided that the NEO remains continually employed by Mylan. |
| RSUs. RSUs generally vest in three annual installments, generally provided that the NEO remains continually employed by Mylan. The NEOs, other than Mr. Parks, received a slightly higher percentage of their long-term incentive awards in the form of RSUs compared to prior years in light of the fact that certain of their PRSUs were not eligible to vest above target as a result of the EPD Transaction in 2015 (despite performance that resulted in vesting above target). The additional RSUs are subject to more rigorous cliff-vesting after a three-year period to further strengthen the Compensation Committees retention objective. |
| PRSUs. PRSUs cliff-vest at the end of the performance period based on the achievement of predetermined performance criteria and provided that the NEO remains continually employed by Mylan. PRSUs vest based on Mylans TSR performance relative to the companies in its peer group (as set forth in the section entitled Peer Group for 2016 on page [●] of this Proxy Statement), and ROIC. The Compensation Committee believes that these two metrics provide an appropriate balance of incentives. Relative TSR rewards the NEOs for performance measured relative to our peer group while ROIC links payouts to returns generated by investments, both organic and through acquisitions. The following table shows the 2016 threshold, target, and maximum goals and relative weightings. |
Metric |
Weighting | Threshold | Target | Maximum | |||||||||||||||||||||||||||
ROIC*
|
50%
|
10%
|
12%
|
14%
|
|||||||||||||||||||||||||||
Relative TSR** |
50%
|
25th Percentile of Peer Group
|
50th Percentile of Peer Group
|
75th Percentile of Peer Group
|
|||||||||||||||||||||||||||
Opportunity
|
N/A
|
50%
|
100%
|
150%
|
* | ROIC is calculated from Mylans audited financial statements in the same manner as set forth in the reconciliations provided in Appendix A. Starting in 2016, the definition of ROIC was updated to include intangible assets and goodwill in the denominator to more appropriately reflect the strategic acquisitions Mylan has made. |
** | Relative TSR is calculated by comparing the difference between Mylans 30-day trailing average closing ordinary share price at the beginning of the performance period and the end of the performance period plus any dividends paid during the performance period against the same metric for each company in our peer group. |
page 50
NEO* |
Position | PRSUs | Options | RSUs | Total Award | |||||
Heather Bresch |
Chief Executive Officer | $4,680,025 | $1,560,009 | $2,756,396 | $8,996,430 | |||||
Kenneth S. Parks |
Chief Financial Officer | $900,022 | $300,000 | $300,007 | $1,500,029 | |||||
Rajiv Malik |
President | $2,700,040 | $900,014 | $1,619,080 | $5,219,134 | |||||
Anthony Mauro |
Chief Commercial Officer | $1,470,044 | $490,013 | $743,837 | $2,703,894 |
* | Mr. Sheehan did not receive a long-term incentive award grant in 2016 due to his announced departure from Mylan. Mr. Coury received a 2016 long-term incentive award grant in his capacity as Executive Chairman prior to his transition to Chairman of the Mylan Board as a Non-Employee Director, which is reflected in the Grants of Plan-Based Awards for 2016 Table on page [●] of this Proxy Statement. |
page 51
page 52
Chairman Payments and Benefits in Connection with Transition
Prior Earned Compensation Settled in 2016 | ||||
Category |
Amount |
Vesting Period | ||
Retirement Benefit Agreement |
Approx. $50.4 million |
2004 2014 | ||
Deferred Separation Payments and Benefits |
Approx. $22.3 million |
Vested in 2012 | ||
Long-Term Incentive Awards |
Approx. $10.7 million |
Upon Mr. Courys satisfaction of retirement eligibility requirements (55 years of age with at least 10 years of service) | ||
Restoration Plan |
Approx. $5.2 million |
Amounts vested upon contribution or, for profit sharing contributions, following an initial 3-year vesting period | ||
Performance Incentive Award Granted in 2014 |
$20 million* | 2014 2016 |
* | Due to SEC reporting requirements for cash awards, this prior grant will be included in this years compensation disclosure, even though it was granted in 2014. |
page 53
Chairman Compensation 2016 2021* | ||
Category |
Amount | |
Cash Retainer |
$450,000 / fiscal quarter | |
Chairman RSUs |
1 million RSUs ($8.7M / year) |
* | In 2016, Mr. Coury received his full long-term incentive grant and a pro-rated bonus for his service during the year as Executive Chairman. As Chairman as a Non-Employee Director, he will no longer receive a salary, annual bonus, or long-term incentive and is not eligible to participate in retirement programs. |
Mr. Courys Total Direct Compensation and All Other Compensation | ||||||
Category |
2015 |
2016 |
Chairman Direct Compensation | |||
Salary / Chairmans Stipend |
$1.4M | $1.6M | $1.8M | |||
2014 Performance Incentive Award (Annualized) |
$6.7M | $6.7M | ||||
Annual Incentive Plan Compensation |
$3.4M | $0.9M | ||||
Annual Long-Term Equity Incentives |
$6.1M | $8.7M | ||||
All Other Compensation* |
$5.2M | $0.4M | ||||
Chairman RSUs (Annualized) |
$8.7M** | |||||
Total |
$22.8M | $18.3M | $10.5M |
* | For 2016, excludes transition related compensation included in the column entitled All Other Compensation in the Summary Compensation Table on page [●] of this Proxy Statement. |
** | RSU grant is annualized over its five-year vesting period. |
page 54
page 55
page 56
AbbVie Inc. | Boston Scientific Corp. | Perrigo Company plc | ||||||
Agilent Technologies Inc. | Bristol-Myers Squibb Company | St. Jude Medical Inc. | ||||||
Allergan plc. | Celgene Corp. | Stryker Corp. | ||||||
Amgen Inc. | Eli Lilly and Company | Teva Pharmaceutical Industries Ltd. | ||||||
Baxter International Inc. | Endo International plc | Thermo Fisher Scientific Inc. | ||||||
Becton Dickinson & Co. | Gilead Sciences, Inc. | Zimmer Biomet Holdings, Inc. | ||||||
Biogen Inc. | Medtronic plc |
page 57
Other Considerations and Executive Compensation Policies
Ordinary Share Ownership Requirements for NEOs
The ownership requirements are expressed as a multiple of base salary as follows:
Position |
Ownership Requirement (multiple of base salary) | |
CEO |
6x | |
President |
4x | |
Other NEOs* |
3x |
* | Excludes Mr. Coury, who is subject to the ordinary share ownership policy for Non-Employee Directors, as described in the section above entitled Non-Employee Director Compensation for 2016 beginning on page [●] of this Proxy Statement, and Mr. Sheehan, who departed from the Company effective April 1, 2016. |
page 58
Summary of Compensation Governance Practices
The Compensation Committee regularly reviews our compensation governance practices to ensure we are incentivizing continued excellence in execution against our long-stated strategy while also managing risk. Below is a summary of the features of our compensation program, as described throughout this CD&A:
What We Do |
What We Dont Do | |
Maintain a significant portion of compensation aligned with shareholder interests and tied to ordinary share price or financial and operational business performance
Balance annual and long-term incentives
Employ balanced and different metrics for annual and long-term incentives
Long-term incentives heavily weighted to performance-based metrics
Double-trigger vesting for annual long-term incentive awards upon a change in control
Consider peer groups and market data in determining compensation
Retain an independent compensation consultant that reports directly to the Compensation Committee
Maintain robust ordinary share ownership guidelines, which our senior management significantly exceeds
Maintain a robust clawback policy
Conduct an annual compensation-related risk review to ensure that compensation is aligned with shareholder interests |
Effective January 1, 2017, discontinued automatic accelerated vesting of stock options, RSUs, and PRSUs upon satisfying retirement eligibility (55 years of age with 10+ years of service)
No exercise of positive discretion in determining annual incentive payouts
No re-pricing of stock options
No hedging or pledging of Company ordinary shares
No new 280G tax gross-ups
No Company matching contributions to the Restoration Plan for NEOs with RBAs |
page 59
page 60
We have reviewed and discussed the CD&A with management. Based on such review and discussions, we recommended to the Mylan Board that the CD&A be included in this Proxy Statement.
Respectfully submitted,
Wendy Cameron
Neil Dimick, C.P.A
Mark W. Parrish
page 61
The following summary compensation table sets forth the cash and non-cash compensation paid or granted to or earned by the NEOs for 2016, 2015, and 2014.
Name and Principal Position |
Fiscal Year |
Salary ($)(3) |
Bonus ($)(4) |
Stock Awards ($)(5) |
Option Awards ($)(6) |
Non-Equity ($)(7) |
Changes in Pension Deferred Compensation Earnings |
All Other Compensation ($)(9) |
Total ($) |
|||||||||||||||||||||||||||
Heather Bresch Chief Executive Officer |
2016 | 1,300,000 | | 7,436,421 | 1,560,009 | 2,276,625 | 506,765 | 696,873 | 13,776,693 | |||||||||||||||||||||||||||
2015 | 1,330,769 | | 5,200,046 | 1,300,007 | 3,900,000 | 768,216 | 6,432,030 | 18,931,068 | ||||||||||||||||||||||||||||
2014 | 1,180,769 | | 4,800,007 | 14,401,997 | 3,259,800 | 1,546,776 | 633,477 | 25,822,826 | ||||||||||||||||||||||||||||
Kenneth S. Parks Chief Financial Officer |
2016 | 346,154 | 375,000 | 2,766,841 | 300,000 | 700,500 | | 18,498 | 4,506,993 | |||||||||||||||||||||||||||
Rajiv Malik President |
2016 | 1,000,000 | | 4,319,120 | 900,014 | 1,459,375 | 616,520 | 390,518 | 8,685,547 | |||||||||||||||||||||||||||
2015 | 1,019,231 | | 3,200,041 | 800,017 | 2,500,000 | 970,676 | 11,411,770 | 19,901,735 | ||||||||||||||||||||||||||||
2014 | 890,385 | | 2,520,003 | 11,946,006 | 1,874,385 | 649,051 | 7,284,822 | 25,164,652 | ||||||||||||||||||||||||||||
Anthony Mauro Chief Commercial Officer |
2016 | 700,000 | | 2,213,881 | 490,013 | 939,838 | | 234,603 | 4,578,335 | |||||||||||||||||||||||||||
2015 | 634,615 | 1,250,036 | 312,517 | 1,437,500 | | 1,216,500 | 4,851,168 | |||||||||||||||||||||||||||||
2014 | 545,192 | | 879,983 | 2,577,505 | 996,050 | | 240,881 | 5,239,611 | ||||||||||||||||||||||||||||
John D. Sheehan Former Executive Vice President and Chief Financial Officer(1) |
2016 | 715,381 | | | | | 278,765 | 167,841 | 1,161,987 | |||||||||||||||||||||||||||
2015 | 675,000 | | 1,560,074 | 390,008 | 1,300,000 | 355,679 | 1,235,718 | 5,516,479 | ||||||||||||||||||||||||||||
2014 | 650,000 | | 1,300,011 | 2,682,497 | 1,177,150 | 341,795 | 177,821 | 6,329,274 | ||||||||||||||||||||||||||||
Robert J. Coury Chairman(2) |
2016 | 1,627,001 | 20,000,000 | 50,805,142 | 1,485,001 | 947,398 | | 22,736,073 | 97,600,615 | |||||||||||||||||||||||||||
2015 | 1,401,923 | | 4,860,067 | 1,215,004 | 3,375,000 | 1,606,533 | 5,242,131 | 17,700,658 | ||||||||||||||||||||||||||||
2014 | 1,350,000 | | 4,320,005 | 10,510,001 | 3,056,063 | 2,404,435 | 883,086 | 22,523,590 |
(1) | Mr. Sheehan departed from Mylan effective April 1, 2016. |
(2) | On June 24, 2016, the Mylan Board approved the transition of Mr. Coury from Executive Chairman of the Mylan Board to the role of Chairman as a Non-Employee Director, as described in the sections above entitled Mr. Courys Transition to Non-Executive Chairman Role and Chairman Transition, beginning on pages [●] and [●], respectively, of this Proxy Statement. |
(3) | Represents the value of the base salary actually paid to the NEO in 2016, 2015, or 2014, except that Mr. Sheehans amount for 2016 also includes Mr. Sheehans consulting payment for three fiscal quarters (total of $487,500) and payment in lieu of accrued vacation ($65,381) and Mr. Courys amount for 2016 also includes Mr. Courys retainer as Chairman as a Non-Employee Director for two fiscal quarters (total of $900,000) and payment in lieu of accrued vacation ($77,963). The annual base salary approved by the Compensation Committee for each of the NEOs is payable in accordance with the Companys normal payroll practices for its senior executives, so that an NEOs total base salary amount is paid to him or her in 26 equal bi-weekly installments. 2015 included an additional payment date (a total of 27 payments were made in 2015), therefore the amounts shown for 2015 are greater than the applicable NEOs annual base salary. |
(4) | For Mr. Parks, represents the value of his sign-on bonus, which is subject to full or partial repayment in the event Mr. Parks leaves Mylan prior to the third anniversary of his joining Mylan. For Mr. Coury, represents the value of his performance incentive opportunity, which was granted in 2014 and fully earned in 2016. |
(5) | Represents the grant date fair value of the stock awards granted to the NEO in 2016, 2015, or 2014, as applicable. The grant date fair value of PRSUs, for 2016, is based on the target value and is as follows: Ms. Bresch ($4,680,025), Mr. Parks ($900,022), Mr. Malik ($2,700,040), Mr. Mauro ($1,470,044), and Mr. Coury ($4,455,014). If the maximum achievement of performance goals had been assumed, the grant date fair value of the PRSUs, for 2016, would have been as follows: Ms. Bresch ($7,020,038), Mr. Parks ($1,350,057), Mr. Malik ($4,050,059), Mr. Mauro ($2,205,089), and Mr. Coury ($6,682,545). For Mr. Parks, the amount shown for 2016 also includes the grant date fair value of PRSUs granted to him under the One-Time Special Performance-Based Incentive Program, which was $1,566,811, which assumes achievement of performance targets at maximum level. For Mr. Coury, the amount shown for 2016 includes the grant date fair value of his one-time five-year Chairmans grant ($43,560,000), 75% of which will generally vest on the third anniversary following the 2016 AGM and the remaining 25% will generally vest on the fifth anniversary following the 2016 AGM, in each case, generally subject to Mr. Courys continued service as Chairman as a Non-Employee Director on such dates. For information regarding assumptions used in determining the expense of such awards, please refer to Note 11 to the Companys Consolidated Financial Statements contained in the Form 10-K for the year ended December 31, 2016. |
(6) | Represents the grant date fair value of the option awards granted to the NEO in 2016, 2015, or 2014, as applicable. For information regarding assumptions used in determining the expense of such awards, please refer to Note 11 to the Companys Consolidated Financial Statements contained in the Form 10-K for the year ended December 31, 2016. For 2014, also includes the grant date fair value of SARs granted under the One-Time Special Performance-Based Incentive Program, which were as follows: $13,202,000 for Ms. Bresch; $11,316,000 for Mr. Malik; $2,357,500 for Messrs. Mauro and Sheehan; and $9,430,000 for Mr. Coury. |
(7) | Represents amounts paid under the Companys non-equity incentive compensation plan. For a discussion of this plan, see the CD&A set forth above. Mr. Sheehan did not receive an award under the Companys non-equity incentive compensation plan for 2016 as a result of his announced departure. In the case of Mr. Coury, due to his transition to Chairman as a Non-Employee Director, his amount was pro-rated to reflect the portion of 2016 during which he was an employee of Mylan. |
(8) | Represents the aggregate change in present value of the applicable NEOs accumulated benefit under his or her respective RBA. In computing these amounts, we used the same assumptions that were used to determine the expense amounts recognized in our 2016 financial statements. In 2016, the impact of a decrease in the applicable discount rates led to an increase in the present value of accumulated benefits of approximately $340,000 for Ms. Bresch, approximately $112,000 for Mr. Malik, and approximately $36,000 for Mr. Sheehan. For further information concerning the RBAs, see the Pension Benefits for 2016 Table set forth below and the section below entitled Retirement Benefit Agreements, beginning on page [●] of this Proxy Statement. |
page 62
(9) | Amounts shown in this column are detailed in the following chart: |
Fiscal Year |
Use of Company- Provided Automobile ($)(a) |
Personal Use of Company Aircraft ($)(b) |
Lodging Reimbursement ($)(c) |
Expatriate Benefits ($)(d) |
401(k) and Plan Matching |
Restoration Plan Contribution ($)(f) |
Transaction- Excise Tax |
Transition Related Benefits ($)(h) |
Other ($)(i) |
|||||||||||||||||||||||||||||||
Heather Bresch |
2016 | 20,507 | 184,020 | | | 29,419 | 302,790 | | | 160,137 | ||||||||||||||||||||||||||||||
2015 | 19,200 | 310,312 | | | 28,792 | 218,454 | 5,828,995 | | 26,277 | |||||||||||||||||||||||||||||||
2014 | 19,200 | 319,050 | | | 27,280 | 224,054 | | | 43,893 | |||||||||||||||||||||||||||||||
Kenneth S. Parks |
2016 | 10,944 | | | | 6,908 | | | | 646 | ||||||||||||||||||||||||||||||
Rajiv Malik |
2016 | 30,725 | 80,295 | | 247,421 | 10,600 | | | | 21,477 | ||||||||||||||||||||||||||||||
2015 | 23,392 | 29,557 | 50,000 | 6,333,891 | | | 4,859,071 | | 115,859 | |||||||||||||||||||||||||||||||
2014 | 29,992 | 32,234 | 50,000 | 7,076,038 | | | | | 96,558 | |||||||||||||||||||||||||||||||
Anthony Mauro |
2016 | 19,200 | 608 | | | 28,335 | 170,589 | | | 15,871 | ||||||||||||||||||||||||||||||
2015 | 19,200 | | | | 28,800 | 131,918 | 1,020,722 | | 15,860 | |||||||||||||||||||||||||||||||
2014 | 19,200 | | | 77,267 | 28,250 | 106,222 | | | 9,942 | |||||||||||||||||||||||||||||||
John D. Sheehan |
2016 | 4,800 | | | | 29,150 | 111,101 | | | 22,790 | ||||||||||||||||||||||||||||||
2015 | 19,200 | 4,506 | | | 28,800 | 100,100 | 1,069,057 | | 14,055 | |||||||||||||||||||||||||||||||
2014 | 19,200 | | | | 28,250 | 114,100 | | | 16,271 | |||||||||||||||||||||||||||||||
Robert J. Coury |
2016 | 34,577 | | | | 29,150 | 293,509 | | 22,292,238 | 86,599 | ||||||||||||||||||||||||||||||
2015 | 38,931 | 605,255 | | | 28,800 | 265,300 | 4,272,289 | | 31,556 | |||||||||||||||||||||||||||||||
2014 | 40,114 | 498,636 | | | 28,250 | 301,088 | | | 14,998 |
(a) | In the case of Ms. Bresch and Messrs. Parks, Mauro, and Sheehan, these numbers represent a vehicle allowance and ancillary expenses associated with such vehicle. In the case of Messrs. Malik and Coury, this number represents the cost of a vehicle (based on lease value), insurance, and ancillary expenses associated with such vehicle. |
(b) | Amounts disclosed represent the actual aggregate incremental costs incurred by Mylan associated with the personal use of the Companys aircraft. Incremental costs include annual average hourly fuel and maintenance costs, landing and parking fees, customs and handling charges, passenger catering and ground transportation, crew travel expenses, away from home hanger fees, and other trip-related variable costs. Because the aircrafts are used primarily for business travel, incremental costs exclude fixed costs that do not change based on usage, such as pilots salaries, aircraft purchase or lease costs, home-base hangar costs, and certain maintenance fees. Aggregate incremental cost as so determined with respect to personal deadhead flights is allocable to the NEO. In certain instances where there are both business and personal passengers, the incremental costs per hour are pro-rated. Mr. Coury fully reimbursed Mylan for any such incremental cost associated with his use of the aircraft in 2016. |
(c) | Beginning in 2016, Mr. Malik was no longer eligible to receive a housing allowance or home leave benefit, both of which he received in prior years. |
(d) | Expatriate benefits for Mr. Malik represent income taxes paid by Mylan in connection with Mr. Maliks expatriate assignment to the United States from India effective January 1, 2012. Specifically, Mr. Malik is responsible for, and has continued to pay taxes equal to those he would have been obligated to pay had he maintained his principal work location and residence in India rather than having transferred, at Mylans request, to the United States, while Mylan generally has responsibility for all additional taxes, including Mr. Maliks tax obligations on the imputed income associated with Mylans payment of taxes on his behalf. Beginning in 2016, Mr. Malik no longer receives a tax equalization benefit in respect of his long-term incentive awards. Amounts shown for 2016, 2015, and 2014 for Mr. Malik are net of Mylans estimated tax refunds for each year. Estimated refunds were approximately $0.2 million for 2016, $1.1 million for 2015, and $1.5 million for 2014. Expatriate benefits for Mr. Mauro represent income taxes paid by the Company in connection with certain long-term incentive awards held by Mr. Mauro relating to a period when he provided services in Canada. |
(e) | In 2016, amounts disclosed included, for Ms. Bresch and Messrs. Parks, Malik, Mauro, Sheehan, and Coury, a matched contribution of $10,869, $6,908, $10,600, $9,785, $10,600, and $10,600, respectively, and, for Ms. Bresch and Messrs. Mauro, Sheehan, and Coury, a profit sharing contribution from the Company of $18,550. In 2015, amounts disclosed for Ms. Bresch included a matched contribution of $10,592, and a profit sharing contribution from the Company of $18,200. In 2015, such amounts for each of Messrs. Mauro, Sheehan, and Coury were $10,600 and $18,200, respectively. In 2014, amounts disclosed for Ms. Bresch included the total of a $17,850 matched contribution and a $9,430 Company profit sharing contribution, and for each of Messrs. Mauro, Sheehan, and Coury such amounts were $17,850 and $10,400, respectively. Mr. Malik became eligible to participate in Mylans U.S. retirement plans in 2016. |
(f) | Represents profit sharing contribution under the Restoration Plan. Ms. Bresch and Messrs. Sheehan and Coury are no longer eligible to receive matching contributions under the Restoration Plan. Although he became eligible to participate in Mylans U.S. retirement plans in 2016, Mr. Malik is not eligible to receive matching contributions under the Restoration Plan. See page [●] of this Proxy Statement for further information regarding Restoration Plan contributions. |
(g) | Represents the one-time tax reimbursement payment with respect to the excise tax under Section 4985 of the Code that was imposed in connection with the EPD Transaction on the value of certain long-term incentive awards held by the directors and NEOs. Such payment ensured that, on a net after-tax basis, the NEO would be in the same position as if such excise tax had not been imposed. See the Proxy Statement for Mylans 2016 Annual Meeting of Shareholders for further discussion of the excise tax imposed in connection with the EPD Transaction and this one-time payment. |
(h) | For Mr. Coury, these amounts are included in the table above entitled Chairman Payments and Benefits in Connection with Transition on page [●] of this Proxy Statement, and represent the value of his deferred separation payments (an amount equal to three times his annual cash compensation (defined as the sum of Mr. Courys base salary as in effect on December 31, 2011, plus the higher of (i) the average annual bonus awarded to Mr. Coury with respect to 2009, 2010, and 2011 or (ii) Mr. Courys 2011 target bonus, $17,443,750) and continued health and other benefits and certain aircraft usage for three years following termination of employment ($265,196 and $4,583,292, respectively), each of which were previously vested and disclosed and became payable in connection with his transition to Chairman as a Non-Employee Director. |
(i) | Represents events and memberships for all NEOs other than Mr. Parks; life insurance retention plan premium for Ms. Bresch and Mr. Mauro; long-term disability premiums; out-of-pocket medical for Mr. Coury; a health insurance premium for Mr. Malik; employee contributions to the Provident Fund, a statutory plan in India, for Mr. Malik; matching of certain charitable contributions for Ms. Bresch and Messrs. Malik, Mauro, and Coury; certain personal security services for Ms. Bresch and Mr. Coury, which for 2016, totaled $104,965 and $41,687, respectively; tax preparation services related to U.K. tax returns for all NEOs other than Mr. Parks; executive physicals for Ms. Bresch and Mr. Sheehan in 2014; and the value ($19,307) of continued health benefits that Mr. Sheehan received in 2016 in connection with his departure from the Company. |
page 63
Grants of Plan-Based Awards for 2016
The following table summarizes grants of plan-based awards made to each NEO during 2016.
Name(1) |
Estimated Future Payments |
Estimated Future Payments |
All Other (#)(4) |
All Other (#)(5) |
Exercise or ($/Sh) |
Grant Date Fair of
Stock ($)(6) |
||||||||||||||||||||||||||||||||||||||||||
Grant Date |
Approval Date |
Threshold ($) |
Target ($) |
Maximum ($) |
Threshold (#) |
Target (#) |
Maximum (#) |
|||||||||||||||||||||||||||||||||||||||||
Heather Bresch |
975,000 | 1,950,000 | 3,900,000 | | | | | | | | ||||||||||||||||||||||||||||||||||||||
2/17/2016 | 2/4/2016 | | | | 50,573 | 101,146 | 151,719 | | | | 4,680,025 | |||||||||||||||||||||||||||||||||||||
2/17/2016 | 2/4/2016 | | | | | | | 59,572 | | | 2,756,396 | |||||||||||||||||||||||||||||||||||||
2/17/2016 | 2/4/2016 | | | | | | | | 86,957 | 46.27 | 1,560,009 | |||||||||||||||||||||||||||||||||||||
Kenneth S. Parks |
300,000 | 600,000 | 1,200,000 | | | | | | | | ||||||||||||||||||||||||||||||||||||||
6/6/2016 | 4/26/2016 | | | | 9,674 | 19,347 | 29,021 | | | | 900,022 | |||||||||||||||||||||||||||||||||||||
10/25/2016 | 10/25/2016 | | | | 20,254 | 40,507 | | | | | 1,566,811 | |||||||||||||||||||||||||||||||||||||
6/6/2016 | 4/26/2016 | | | | | | | 6,449 | | | 300,007 | |||||||||||||||||||||||||||||||||||||
6/6/2016 | 4/26/2016 | | | | | | | | 16,549 | 46.52 | 300,000 | |||||||||||||||||||||||||||||||||||||
Rajiv Malik |
625,000 | 1,250,000 | 2,500,000 | | | | | | | | ||||||||||||||||||||||||||||||||||||||
2/17/2016 | 2/4/2016 | | | | 29,177 | 58,354 | 87,531 | | | | 2,700,040 | |||||||||||||||||||||||||||||||||||||
2/17/2016 | 2/4/2016 | | | | | | | 34,992 | | | 1,619,080 | |||||||||||||||||||||||||||||||||||||
2/17/2016 | 2/4/2016 | | | | | | | | 50,168 | 46.27 | 900,014 | |||||||||||||||||||||||||||||||||||||
Anthony Mauro |
402,500 | 805,000 | 1,610,000 | | | | | | | | ||||||||||||||||||||||||||||||||||||||
2/17/2016 | 2/4/2016 | | | | 15,886 | 31,771 | 47,657 | | | | 1,470,044 | |||||||||||||||||||||||||||||||||||||
2/17/2016 | 2/4/2016 | | | | | | | 16,076 | | | 743,837 | |||||||||||||||||||||||||||||||||||||
2/17/2016 | 2/4/2016 | | | | | | | | 27,314 | 46.27 | 490,013 | |||||||||||||||||||||||||||||||||||||
Robert J. Coury |
843,750 | 1,687,500 | 3,375,000 | | | | | | | | ||||||||||||||||||||||||||||||||||||||
2/17/2016 | 2/4/2016 | | | | 48,142 | 96,283 | 144,425 | | | | 4,455,014 | |||||||||||||||||||||||||||||||||||||
2/17/2016 | 2/4/2016 | | | | | | | 60,301 | | | 2,790,127 | |||||||||||||||||||||||||||||||||||||
6/24/2016 | 6/3/2016 | | | | | | | 1,000,000 | | | 43,560,000 | |||||||||||||||||||||||||||||||||||||
2/17/2016 | 2/4/2016 | | | | | | | | 82,776 | 46.27 | 1,485,001 |
(1) | As a result of his announced departure from the Company, Mr. Sheehan did not receive any grants of plan-based awards in 2016. |
(2) | The performance goals under the annual incentive compensation program applicable to the NEOs during 2016 are described above in the CD&A. |
(3) | Represents the grant of PRSUs awarded under the Amended 2003 Plan. For Mr. Parks, the PRSUs granted on October 25, 2016 were granted under the One-Time Special Performance-Based Incentive Program. The vesting terms applicable to these awards are described above in the CD&A and below in the footnotes to the Outstanding Equity Awards at the End of 2016 Table. |
(4) | Represents the grant of RSUs awarded under the Amended 2003 Plan. For Mr. Coury, the RSUs granted on June 24, 2016 consist of his one-time Chairman award, which is described in the section above entitled Chairman Transition beginning on page [●] of this Proxy Statement. The vesting terms applicable to these awards are described below in the footnotes to the Outstanding Equity Awards at the End of 2016 Table. |
(5) | Represents the grant of ten-year stock options awarded under the Amended 2003 Plan. Stock options were granted with an exercise price equal to the closing price of the Companys ordinary shares on the date of grant. The vesting terms applicable to these awards are described below in the footnotes to the Outstanding Equity Awards at the End of 2016 Table. |
(6) | Represents the grant date fair value of the specific award granted to the NEO. For information regarding assumptions used in determining such value, please refer to Note 11 to the Companys Consolidated Financial Statements contained in the Form 10-K for the year ended December 31, 2016. |
page 64
Outstanding Equity Awards at the End of 2016
The following table sets forth information concerning all of the outstanding long-term incentive awards held by each NEO as of December 31, 2016.
Option Awards | Stock Awards | |||||||||||||||||||||||||||||||
Name |
Number of Securities Underlying Unexercised Options (#) Exercisable |
Number of Securities Underlying Unexercised Options (#) Unexercisable(1) |
Option Exercise Price ($) |
Option Expiration Date |
Number of Shares or Units of Stock That Have Not Vested (#)(2) |
Market or Units
of |
Equity Have Not |
Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($)(3) |
||||||||||||||||||||||||
Heather Bresch |
14,196 | | 21.13 | 3/3/2020 | | | | | ||||||||||||||||||||||||
4,413 | | 22.66 | 3/2/2021 | | | | | |||||||||||||||||||||||||
4,266 | | 23.44 | 2/22/2022 | | | | | |||||||||||||||||||||||||
3,236 | | 30.90 | 3/6/2023 | | | | | |||||||||||||||||||||||||
43,668 | 21,834 | 55.84 | 3/5/2024 | | | | | |||||||||||||||||||||||||
22,553 | 45,106 | 50.66 | 11/17/2025 | | | | | |||||||||||||||||||||||||
| 86,957 | 46.27 | 2/17/2026 | | | | | |||||||||||||||||||||||||
| | | | | | 378,071 | (4) | 14,423,409 | ||||||||||||||||||||||||
| | | | 17,108 | 652,670 | 76,984 | (5) | 2,936,940 | ||||||||||||||||||||||||
| | | | 59,572 | 2,272,672 | 101,146 | (5) | 3,858,720 | ||||||||||||||||||||||||
Kenneth S. Parks |
| 16,549 | 46.52 | 6/6/2026 | | | | | ||||||||||||||||||||||||
| | | | | | 40,507 | (4) | 1,545,342 | ||||||||||||||||||||||||
| | | | 6,449 | 246,029 | 19,347 | (5) | 738,088 | ||||||||||||||||||||||||
Rajiv Malik |
22,926 | 11,463 | 55.84 | 3/5/2024 | | | | | ||||||||||||||||||||||||
13,879 | 27,758 | 50.66 | 11/17/2025 | | | | | |||||||||||||||||||||||||
| 50,168 | 46.27 | 2/17/2026 | | | | | |||||||||||||||||||||||||
| | | | | | 324,061 | (4) | 12,362,927 | ||||||||||||||||||||||||
| | | | 10,528 | 401,643 | 47,375 | (5) | 1,807,356 | ||||||||||||||||||||||||
| | | | 34,992 | 1,334,945 | 58,354 | (5) | 2,226,205 | ||||||||||||||||||||||||
Anthony Mauro |
4,757 | | 22.66 | 3/2/2021 | | | | | ||||||||||||||||||||||||
4,266 | | 23.44 | 2/22/2022 | | | | | |||||||||||||||||||||||||
3,236 | | 30.90 | 3/6/2023 | | | | | |||||||||||||||||||||||||
8,006 | 4,003 | 55.84 | 3/5/2024 | | | | | |||||||||||||||||||||||||
5,422 | 10,843 | 50.66 | 11/17/2025 | | | | | |||||||||||||||||||||||||
| 27,314 | 46.27 | 2/17/2026 | | | | | |||||||||||||||||||||||||
| | | | | | 67,512 | (4) | 2,575,583 | ||||||||||||||||||||||||
| | | | 4,112 | 156,873 | 18,506 | (5) | 706,004 | ||||||||||||||||||||||||
| | | | 16,076 | 613,299 | 31,771 | (5) | 1,212,064 | ||||||||||||||||||||||||
John D. Sheehan |
17,740 | | 55.84 | 3/5/2024 | | | | | ||||||||||||||||||||||||
20,298 | | 50.66 | 11/17/2025 | | | | | |||||||||||||||||||||||||
Robert J. Coury |
14,196 | | 21.13 | 3/3/2020 | | | | | ||||||||||||||||||||||||
4,413 | | 22.66 | 3/2/2021 | | | | | |||||||||||||||||||||||||
4,266 | | 23.44 | 2/22/2022 | | | | | |||||||||||||||||||||||||
3,236 | | 30.90 | 3/6/2023 | | | | | |||||||||||||||||||||||||
58,952 | | 55.84 | 3/5/2024 | | | | | |||||||||||||||||||||||||
63,235 | | 50.66 | 11/17/2025 | | | | | |||||||||||||||||||||||||
82,776 | | 46.27 | 2/17/2026 | |||||||||||||||||||||||||||||
| | | | | | 270,051 | (4) | 10,302,446 | ||||||||||||||||||||||||
| | | | 1,000,000 | 38,150,000 | | |
page 65
(1) | Vesting dates applicable to unvested stock options are as follows, in each case generally subject to continued employment with Mylan: on March 5, 2017, the unvested options at the $55.84 exercise price for Ms. Bresch and Messrs. Malik and Mauro vested; on March 4, 2017, one-half of the unvested options at the $50.66 exercise price for Ms. Bresch and Messrs. Malik and Mauro vested, and the remaining options will vest on March 4, 2018; on February 17, 2017, one-third of the unvested options at the $46.27 exercise price for Ms. Bresch and Messrs. Malik and Mauro vested and one-third of the unvested options at the $46.52 exercise price for Mr. Parks vested, and, in each case, the remaining options will vest 50% on each of February 17, 2018 and 2019. Subject to applicable employment agreement provisions, following termination of employment, vested stock options will generally remain exercisable for 30 days following termination, except that (i) in the case of termination because of disability, 100% of options become vested and vested options will remain exercisable for two years following termination; (ii) in the case of a termination due to a reduction in force, vested options will remain exercisable for one year following termination; (iii) in the case of death, including within two years following termination because of disability, or, in the case of options granted prior to January 1, 2017, retirement, 100% of options become vested and vested options will remain exercisable for the remainder of the original term; and (iv) in the case of an involuntary termination without cause or a voluntary resignation for good reason that occurs within two years following a change in control, 100% of options become vested (double-trigger awards). In the case of options granted in 2013, 2014, 2015, or 2016 to Ms. Bresch, and in 2014, 2015, or 2016 to Mr. Malik, following termination of employment without cause or resignation for good reason as defined in the applicable employment agreement, 100% of options become vested and vested options will remain exercisable for one year following termination. |
(2) | One-half of Ms. Breschs 17,108 RSUs, Mr. Maliks 10,528 RSUs, and Mr. Mauros 4,112 RSUs vested on March 4, 2017, and the remainder will vest on March 4, 2018. All of the other RSUs in the column for Ms. Bresch and Messrs. Parks, Malik, and Mauro vested one-third on February 17, 2017, and the remaining such RSUs will vest 50% on each of February 17, 2018 and 2019. In accordance with their terms, all of these awards would vest upon an involuntary termination without cause or a voluntary resignation for good reason that occurs within two years following a change in control (double trigger awards) or upon the executives death or disability. In the case of awards granted to Ms. Bresch and Mr. Malik the awards would also vest upon the executives termination without cause, or resignation for good reason as defined in the applicable employment agreement. In the case of Mr. Coury, represents his one-time five-year Chairmans award, which is scheduled to vest 75% on the third anniversary following the 2016 AGM and 25% on the fifth anniversary following the 2016 AGM, except that the award would also vest upon the termination of Mr. Courys service as Chairman as a Non-Employee Director due to his death or disability or without cause or his resignation for good reason as defined in the letter agreement relating to Mr. Courys transition. |
(3) | The market value of restricted ordinary shares, RSUs, and PRSUs was calculated using the closing price of the Companys ordinary shares as of December 31, 2016. In the case of Mr. Coury, the value includes his one-time five-year Chairmans award. |
(4) | These awards consist of restricted ordinary shares under the One-Time Special Performance-Based Incentive Program. The restricted ordinary shares remain subject to forfeiture and additional vesting conditions, including achievement of adjusted EPS of $6.00 for full vesting and continued service through December 31, 2018, and the other terms and conditions of the program. The One-Time Special Performance-Based Incentive Program is described in detail in the Form 10-K/A for Mylan Inc.s fiscal year ending December 31, 2014. In accordance with their terms, the restricted ordinary shares would vest upon a change in control. In the case of awards granted to Ms. Bresch and Mr. Malik, the restricted ordinary shares would also vest upon the executives termination due to death or disability or without cause or resignation for good reason as defined in the applicable employment agreement, subject to the achievement of the applicable performance goals, except that, if such termination or resignation occurred prior to January 1, 2017, only a pro-rated portion of the restricted ordinary shares would have vested. In the case of awards granted to Mr. Coury, the restricted ordinary shares would also vest upon the involuntary termination of his service as Chairman as a Non-Employee Director due to death or disability or without cause or his resignation for good reason as defined in the letter agreement relating to Mr. Courys transition. |
(5) | The vesting of these PRSUs is subject to the attainment of performance goals. On March 4, 2018, Ms. Bresch is expected to vest in PRSUs relating to 76,984 ordinary shares, Mr. Malik is expected to vest in PRSUs relating to 47,375 ordinary shares, and Mr. Mauro is expected to vest in PRSUs relating to 18,506 ordinary shares. On February 17, 2019, Ms. Bresch is expected to vest in PRSUs relating to 101,146 ordinary shares, Mr. Parks is expected to vest in PRSUs relating to 19,347 ordinary shares, Mr. Malik is expected to vest in PRSUs relating to 58,354 ordinary shares, and Mr. Mauro is expected to vest in PRSUs relating to 31,771 ordinary shares. The PRSUs are expected to vest upon the earliest to occur of (i) March 4, 2018 or February 17, 2019, as applicable, provided that the performance goals have been satisfied, (ii) an involuntary termination without cause or a voluntary resignation for good reason within two years following the change in control, (iii) the executives death or disability, and (iv) in the case of awards granted to Ms. Bresch and Mr. Malik, the executives termination without cause, or resignation for good reason as defined in the applicable employment agreement. Any outstanding ordinary shares subject to the award that remain unvested as of March 4, 2018 or February 17, 2019, as applicable, will be forfeited. |
Option Exercises and Stock Vested for 2016
The option awards and ordinary share awards reflected in the table below were exercised or became vested for the NEOs during 2016. In the case of Mr. Coury, a portion of the vested ordinary share awards reflected below were included in the table above entitled Chairman Payments and Benefits in Connection with Transition on page [●] of this Proxy Statement.
Option Awards | Stock Awards | |||||||||||||||
Name |
Number of Shares Acquired on Exercise (#) |
Value Realized on Exercise |
Number of Shares Acquired on Vesting (#) |
Value Realized on Vesting ($) |
||||||||||||
Heather Bresch |
| | 8,554 | 383,048 | ||||||||||||
Kenneth S. Parks |
| | | | ||||||||||||
Rajiv Malik |
| | 5,264 | 235,722 | ||||||||||||
Anthony Mauro |
| | 2,057 | 92,112 | ||||||||||||
John D. Sheehan |
20,741 | 451,614 | 2,567 | 114,950 | ||||||||||||
Robert J. Coury(1) |
| | 252,519 | 11,009,482 |
(1) | Since he was retirement eligible at the time of his transition to Chairman as a Non-Employee Director, Mr. Coury was eligible for accelerated vesting of his outstanding RSUs and PRSUs in accordance with the terms of his award agreements. The value of those accelerated awards was $10,651,465 on June 24, 2016, the time at which such awards became vested, and $9,098,738 on December 28, 2016, the time at which such awards were settled. |
page 66
The following table summarizes the benefits accrued by the NEOs as of December 31, 2016 under the RBA (or Executive Plan, in the case of Mr. Malik) in effect with the NEOs during 2016. The Company does not sponsor any other defined benefit pension programs covering the NEOs.
Name |
Plan Name(1) | Number of Years Credited Service |
Present Value of Accumulated Benefit ($)(2) |
Payments During Last Fiscal Year ($) |
||||||||
Heather Bresch |
Retirement Benefit Agreement | 12 | 6,933,326 | | ||||||||
Kenneth S. Parks |
N/A | N/A | N/A | N/A | ||||||||
Rajiv Malik |
The Executive Plan for Rajiv Malik(3) | N/A | 308,496 | | ||||||||
Rajiv Malik |
Retirement Benefit Agreement | 10 | 4,301,387 | | ||||||||
Anthony Mauro |
N/A | N/A | N/A | N/A | ||||||||
John D. Sheehan |
Retirement Benefit Agreement | 6 | | 1,492,196 | ||||||||
Robert J. Coury |
Retirement Benefit Agreement | 15 | | 50,437,336 | (4) |
(1) | Messrs. Parks and Mauro are not party to an RBA. |
(2) | See page [●] of this Proxy Statement for further information on the value of the accumulated pension benefit. |
(3) | This is a deferred compensation plan established for the benefit of Mr. Malik. The Company is no longer contributing to this plan. |
(4) | This amount, which reflects the distribution Mr. Coury received under his RBA in connection with his transition to Chairman as a Non-Employee Director, is included in the table above entitled Chairman Payments and Benefits in Connection with Transition on page [●] of this Proxy Statement. |
Nonqualified Deferred Compensation
The following table sets forth information relating to the Restoration Plan for 2016. There was no NEO participation in the Mylan Executive Income Deferral Plan in 2016.
Name |
Aggregate Balance at Last FYE ($) |
Executive Contributions in Last FY ($) |
Company Profit Sharing in Last FY |
Aggregate Earnings (Loss) in Last FY ($)(1) |
Aggregate Withdrawals/ Distributions ($) |
Aggregate Balance at FYE ($) |
||||||||||||||||||
Heather Bresch |
2,552,723 | | 302,790 | 166,839 | | 3,022,352 | ||||||||||||||||||
Kenneth S. Parks |
N/A | N/A | N/A | N/A | N/A | N/A | ||||||||||||||||||
Rajiv Malik |
N/A | N/A | N/A | N/A | N/A | N/A | ||||||||||||||||||
Anthony Mauro |
996,720 | 74,992 | 170,589 | 96,125 | | 1,338,426 | ||||||||||||||||||
John D. Sheehan |
1,345,163 | | 111,101 | 84,631 | 1,540,895 | | ||||||||||||||||||
Robert J. Coury |
4,493,138 | | 293,509 | 425,661 | 5,212,308 | (2) | |
(1) | These amounts include earnings (losses), dividends, and interest provided on account balances, including the change in value of the underlying investments in which our NEOs are deemed to be invested. These amounts are not reported in the Summary Compensation Table. |
(2) | This amount reflects the distribution Mr. Coury received from the Restoration Plan in accordance with the terms of the Restoration Plan in connection with his transition to Chairman as a Non-Employee Director, and is included in the table above entitled Chairman Payments and Benefits in Connection with Transition on page [●] of this Proxy Statement. |
page 67
page 68
page 69
page 70
page 71
page 72
Voting Item 5 Approval, on an Advisory Basis, of the Compensation of the Named Executive Officers of the Company
|
page 73
Voting Item 6 Advisory Vote on the Frequency of the Say-on-Pay Vote
|
page 74
Voting Item 7 Authorization of the Mylan Board to Acquire Ordinary Shares and Preferred Shares in the Capital of the Company
|
THE MYLAN BOARD UNANIMOUSLY RECOMMENDS A VOTE FOR THE AUTHORIZATION OF THE MYLAN BOARD TO ACQUIRE ORDINARY SHARES AND PREFERRED SHARES IN THE CAPITAL OF THE COMPANY.
page 75
Compensation Committee Interlocks and Insider Participation
Certain Relationships and Related Transactions
page 76
page 77
Proposals for the 2018 Annual General Meeting of Shareholders
page 78
2016 Annual Report on Form 10-K
page 79
Appendix A Reconciliation of Non-GAAP Measures (Unaudited)
Year Ended December 31, | ||||||||
(In millions, except per share amounts) | 2016 | |||||||
U.S. GAAP net earnings attributable to Mylan N.V. and U.S. GAAP diluted earnings per share |
$ | 480.0 | $ | 0.92 | ||||
Purchase accounting related amortization (primarily included in cost of sales) |
1,412.3 | |||||||
Litigation settlements, net |
638.5 | |||||||
Interest expense (primarily related to clean energy investment financing) |
24.4 | |||||||
Accretion of contingent consideration liability and other fair value adjustments |
75.4 | |||||||
Clean energy investments pre-tax loss |
92.3 | |||||||
Acquisition related costs (primarily included in SG&A, other expense, net and interest expense) |
335.3 | |||||||
Restructuring related costs |
149.7 | |||||||
Other special items included in: |
||||||||
Cost of sales |
44.6 | |||||||
Research and development expense |
121.3 | |||||||
Selling, general and administrative expense |
35.5 | |||||||
Other (income) expense, net |
(18.5 | ) | ||||||
Tax effect of the above items and other income tax related items |
(843.5 | ) | ||||||
|
|
|||||||
Adjusted net earnings attributable to Mylan N.V. and adjusted diluted EPS(a) |
$ | 2,547.3 | $ | 4.89 | ||||
|
|
|
|
|||||
Weighted average diluted ordinary shares outstanding |
520.5 | |||||||
|
|
(a) | Adjusted EPS for the year ended December 31, 2016 had a favorable foreign currency impact of $0.04 per ordinary share |
Year Ended December 31, |
||||
(in millions) | 2016 | |||
U.S. GAAP net cash provided by operating activities |
$ | 2,047.2 | ||
Add / (Deduct): |
||||
Payment of litigation settlements |
68.5 | |||
Financing related expenses |
66.9 | |||
Acquisition related costs |
244.4 | |||
R&D expense |
123.2 | |||
Income tax items |
(25.8 | ) | ||
|
|
|||
Adjusted cash provided by operating activities |
$ | 2,524.4 | ||
|
|
|||
Deduct: |
||||
Capital expenditures |
(390.4 | ) | ||
|
|
|||
Adjusted free cash flow |
$ | 2,134.0 | ||
|
|
A-1
Year Ended December 31, |
||||
(In millions) | 2016 | |||
Adjusted net earnings attributable to Mylan N.V. and adjusted diluted EPS |
$ | 2,547 | ||
Add / (Deduct): |
||||
Tax effect of non-GAAP adjustments and other income tax related items |
844 | |||
U.S. GAAP reported income tax (benefit) provision |
(358 | ) | ||
|
|
|||
Adjusted pre-tax income |
$ | 3,033 | ||
|
|
Year Ended December 31, |
||||
(In millions) | 2016 | |||
U.S. GAAP interest expense |
$ | 455 | ||
Deduct: |
||||
Interest expense related to clean energy investments |
(14 | ) | ||
Accretion of contingent consideration liability |
(41 | ) | ||
Acquisition related costs |
(46 | ) | ||
Other special items |
(10 | ) | ||
|
|
|||
Adjusted interest expense |
$ | 343 | ||
|
|
A-2
Return on Invested Capital
Year Ended December 31, |
||||||||
(Unaudited; in millions, except %) | 2016 | |||||||
Adjusted pre-tax income |
$ | 3,033 | ||||||
Adjusted interest expense |
343 | |||||||
|
|
|||||||
Adjusted income before interest and tax |
3,376 | |||||||
Estimated adjusted income tax expense(a) |
(540 | ) | ||||||
|
|
|||||||
Adjusted net operating profit after tax |
$ | 2,835 |
As of December 31, |
||||
2015 | ||||
Total assets |
$ | 29,003 | ||
Cash & near cash items |
(2,211 | ) | ||
Short-term investments |
(98 | ) | ||
Current deferred income taxes |
(0 | ) | ||
Non-current deferred income taxes |
(460 | ) | ||
Forward starting swaps |
40 | |||
Clean Coal |
(363 | ) | ||
Restricted cash |
(215 | ) | ||
|
|
|||
Total invested assets |
$ | 25,697 | ||
Accounts payable |
(1,161 | ) | ||
Other current liabilities |
(2,472 | ) | ||
Income taxes payable |
(104 | ) | ||
|
|
|||
Total invested capital |
$ | 21,959 | ||
|
|
|||
Intangible assets |
10,456 | |||
Goodwill |
7,128 | |||
|
|
|||
Operational invested capital |
$ | 4,375 | ||
|
|
Cash Return on Total Invested Capital(b) |
13 | % | ||||||
Cash Return on Operational Invested Capital(c) |
65 | % |
(a) | Estimated adjusted income tax expense is the adjusted income tax rate multipled by adjusted income before interest and tax. |
(b) | Calculated using adjusted net operating profit after tax / total invested capital. This is the ROIC metric for awards granted in 2016. |
(c) | Calculated using adjusted net operating profit after tax / operational invested capital. This is the ROIC metric for awards granted prior to 2016. |
A-3
Mylan
Better Health
For a Better World
YOUR VOTE IS IMPORTANT
Please take a moment prior to the Cut-Off Time specified in the proxy statement ([●] Central European Time (CET) / [●] Eastern Time (ET) on June [●], 2017) to vote your ordinary shares of Mylan N.V. for the upcoming annual general meeting of shareholders.
PLEASE REVIEW THE PROXY STATEMENT AND VOTE TODAY IN ONE OF THREE WAYS:
1. | Vote by TelephonePlease call toll-free in the U.S. or Canada at [●], on a touch-tone phone. If outside the U.S. or Canada, call [●]. Please follow the simple instructions. You will be required to provide the unique control number printed below. |
OR
2. | Vote by InternetPlease access https://www.proxyvotenow.com/myl, and follow the simple instructions. Please note you must type an s after http. You will be required to provide the unique control number printed below. |
You may vote by telephone or Internet 24 hours a day, 7 days a week. Your telephone or Internet vote authorizes the named proxies to vote your shares in the same manner as if you had marked, signed and returned a proxy card. |
OR
3. | Vote by MailIf you do not wish to vote by telephone or over the Internet, please complete, sign, date and return the proxy card in the envelope provided, or mail to: Mylan N.V., c/o Innisfree M&A Incorporated, FDR Station, P.O. Box 5155, New York, NY 10150-5155. |
q TO VOTE BY MAIL, PLEASE DETACH PROXY CARD HERE AND SIGN, DATE AND RETURN IN THE POSTAGE-PAID ENVELOPE PROVIDED q
To vote, mark blocks below in blue or black ink as follows | THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR EACH DIRECTOR IN ITEM 1 AND FOR ITEMS 2, 3, 4, 5, AND 7 AND 1 YEAR ON ITEM 6. |
Company Proposals (Items 1 through 7) | ||||||||||||||||||||||||||||||||||||
1. | Appointment of the following 11 directors, each for a term until immediately after the next annual general meeting:
|
|||||||||||||||||||||||||||||||||||
FOR
|
AGAINST
|
ABSTAIN
|
FOR
|
AGAINST
|
ABSTAIN
|
FOR
|
AGAINST
|
ABSTAIN
|
||||||||||||||||||||||||||||
A. | Heather Bresch | ☐ | ☐ | ☐ | G. | Melina Higgins | ☐ | ☐ | ☐ | 2. | Adoption of the Dutch annual accounts for fiscal year 2016
|
☐ | ☐ | ☐ | ||||||||||||||||||||||
B. | Wendy Cameron | ☐ | ☐ | ☐ | H. | Rajiv Malik | ☐ | ☐ | ☐ | 3. | Ratification of the selection of Deloitte & Touche LLP as the Companys independent registered public accounting firm for fiscal year 2017 | ☐ | ☐ | ☐ | ||||||||||||||||||||||
C. |
Hon. Robert J. Cindrich |
☐ |
☐ |
☐ |
I. |
Mark W. Parrish |
☐ |
☐ |
☐ |
|||||||||||||||||||||||||||
D. |
Robert J. Coury |
☐ |
☐ |
☐ |
J. |
Randall L. (Pete) Vanderveen, Ph.D., R.Ph. |
☐ |
☐ |
☐ |
4. |
Instruction to Deloitte Accountants B.V. for the audit of the Companys Dutch statutory annual accounts for fiscal year 2017 |
☐ |
☐ |
☐ |
||||||||||||||||||||||
E. |
JoEllen Lyons Dillon |
☐ |
☐ |
☐ |
K. |
Sjoerd S. Vollebregt |
☐ |
☐ |
☐ |
|||||||||||||||||||||||||||
F. |
Neil Dimick, C.P.A. |
☐ |
☐ |
☐ |
5. |
Approval, on an advisory basis, of the compensation of the named executive officers of the Company (the Say-on-Pay Vote)
|
☐ |
☐ |
☐ |
|||||||||||||||||||||||||||
1 YEAR | 2 YEARS | 3 YEARS | ABSTAIN | |||||||||||||||||||||||||||||||||
6. |
Advisory vote on the frequency of the Say-on-Pay Vote |
☐ |
☐ |
☐ |
☐ |
|||||||||||||||||||||||||||||||
7. |
Authorization of the Mylan Board to acquire ordinary shares and preferred shares in the capital of the Company
|
☐ |
☐ |
☐ |
||||||||||||||||||||||||||||||||
Date: |
|
, 2017 | ||||||||||||||||||||||
|
||||||||||||||||||||||||
Signature | ||||||||||||||||||||||||
|
||||||||||||||||||||||||
Signature (if held jointly) | ||||||||||||||||||||||||
|
||||||||||||||||||||||||
Title
|
||||||||||||||||||||||||
NOTE: Please sign exactly as your name(s) appear(s) hereon. When shares are held jointly, joint owners should each sign. Executors, administrators, trustees, etc., should indicate the capacity in which signing. If a corporation, please sign in full | ||||||||||||||||||||||||
corporate name by an authorized officer. If a partnership, please sign in partnership name by authorized person. |
PLEASE VOTE TODAY!
SEE REVERSE SIDE
FOR THREE EASY WAYS TO VOTE.
Important Notice Regarding the Availability of Proxy Materials |
for the Shareholder Meeting To Be Held on Thursday, June 22, 2017 |
The Notice of the Meeting, Proxy Statement, Proxy Card, Annual Report on Form 10-K (as amended) and the |
Dutch Board Report are available at mylan.com/investors
|
q TO VOTE BY MAIL, PLEASE DETACH PROXY CARD HERE, AND SIGN, DATE AND RETURN IN THE ENVELOPE PROVIDED q
|
Preliminary Copy
MYLAN N.V.
PROXY FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS
To Be Held on June 22, 2017 at [●] Central European Time (CET) at [●]
This Proxy is Solicited on Behalf of the Board of Directors of Mylan N.V. (the Mylan Board)
PROXY VOTING DEADLINE: [●] CENTRAL EUROPEAN TIME (CET) / [●] EASTERN TIME (ET), [●], 2017
The undersigned hereby appoints [●] and [●], and each with full power to act without the other, as proxies, with full power of substitution, for and in the name of the undersigned to vote and act with respect to all ordinary shares of MYLAN N.V. (Mylan or the Company) which the undersigned is entitled to vote and act at the Annual General Meeting of Shareholders of Mylan to be held on June 22, 2017, with all the powers the undersigned would possess if personally present, and particularly, but without limiting the generality of the foregoing:
This proxy, when properly executed, will be voted in the manner directed herein. This proxy will be voted FOR each director in Item 1 and FOR Items 2, 3, 4, 5, and 7 and 1 YEAR in Item 6 if no choice is specified. The proxies are hereby authorized to vote in their discretion upon such other matters as may properly come before the meeting.
(Continued and to be signed on the reverse side) |
YOUR VOTE IS IMPORTANT
Please take a moment prior to [●] Eastern Time (ET) on June [●], 2017 to vote your ordinary shares of Mylan N.V. for the upcoming annual general meeting of shareholders.
PLEASE REVIEW THE PROXY STATEMENT AND VOTE TODAY IN ONE OF THREE WAYS:
1. | Vote by TelephonePlease call toll-free in the U.S. or Canada at [●], on a touch-tone phone. If outside the U.S. or Canada, call [●]. Please follow the simple instructions. You will be required to provide the unique control number printed below. |
OR
2. | Vote by InternetPlease access https://www.proxyvotenow.com/myl-plans, and follow the simple instructions. Please note you must type an s after http. You will be required to provide the unique control number printed below. |
You may vote by telephone or Internet 24 hours a day, 7 days a week. Your telephone or Internet vote authorizes the named proxies to vote your shares in the same manner as if you had marked, signed and returned a proxy card. |
OR
3. | Vote by MailIf you do not wish to vote by telephone or over the Internet, please complete, sign, date and return the proxy card in the envelope provided, or mail to: Mylan N.V., c/o Innisfree M&A Incorporated, FDR Station, P.O. Box 5155, New York, NY 10150-5155. |
q TO VOTE BY MAIL, PLEASE DETACH PROXY CARD HERE AND SIGN, DATE AND RETURN IN THE POSTAGE-PAID ENVELOPE PROVIDED q
To vote, mark blocks below in blue or black ink as follows | THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR EACH DIRECTOR IN ITEM 1 AND FOR ITEMS 2, 3, 4, 5, AND 7 AND 1 YEAR ON ITEM 6. |
Company Proposals (Items 1 through 7) | ||||||||||||||||||||||||||||||||||||
1. | Appointment of the following 11 directors, each for a term until immediately after the next annual general meeting:
|
|||||||||||||||||||||||||||||||||||
FOR
|
AGAINST
|
ABSTAIN
|
FOR
|
AGAINST
|
ABSTAIN
|
FOR
|
AGAINST
|
ABSTAIN
|
||||||||||||||||||||||||||||
A. | Heather Bresch | ☐ | ☐ | ☐ | G. | Melina Higgins | ☐ | ☐ | ☐ | 2. | Adoption of the Dutch annual accounts for fiscal year 2016
|
☐ | ☐ | ☐ | ||||||||||||||||||||||
B. | Wendy Cameron | ☐ | ☐ | ☐ | H. | Rajiv Malik | ☐ | ☐ | ☐ | 3. | Ratification of the selection of Deloitte & Touche LLP as the Companys independent registered public accounting firm for fiscal year 2017 | ☐ | ☐ | ☐ | ||||||||||||||||||||||
C. |
Hon. Robert J. Cindrich |
☐ |
☐ |
☐ |
I. |
Mark W. Parrish |
☐ |
☐ |
☐ |
|||||||||||||||||||||||||||
D. |
Robert J. Coury |
☐ |
☐ |
☐ |
J. |
Randall L. (Pete) Vanderveen, Ph.D., R.Ph. |
☐ |
☐ |
☐ |
4. |
Instruction to Deloitte Accountants B.V. for the audit of the Companys Dutch statutory annual accounts for fiscal year 2017 |
☐ |
☐ |
☐ |
||||||||||||||||||||||
E. |
JoEllen Lyons Dillon |
☐ |
☐ |
☐ |
K. |
Sjoerd S. Vollebregt |
☐ |
☐ |
☐ |
|||||||||||||||||||||||||||
F. |
Neil Dimick, C.P.A. |
☐ |
☐ |
☐ |
5. |
Approval, on an advisory basis, of the compensation of the named executive officers of the Company (the Say-on-Pay Vote)
|
☐ |
☐ |
☐ |
|||||||||||||||||||||||||||
1 YEAR | 2 YEARS | 3 YEARS | ABSTAIN | |||||||||||||||||||||||||||||||||
6. |
Advisory vote on the frequency of the Say-on-Pay Vote |
☐ |
☐ |
☐ |
☐ |
|||||||||||||||||||||||||||||||
7. |
Authorization of the Mylan Board to acquire ordinary shares and preferred shares in the capital of the Company
|
☐ |
☐ |
☐ |
||||||||||||||||||||||||||||||||
Date: |
|
, 2017 | ||||||||||||||||||||||
|
||||||||||||||||||||||||
Signature | ||||||||||||||||||||||||
|
||||||||||||||||||||||||
Signature (if held jointly) | ||||||||||||||||||||||||
|
||||||||||||||||||||||||
Title
|
||||||||||||||||||||||||
NOTE: Please sign exactly as your name(s) appear(s) hereon. When shares are held jointly, joint owners should each sign. Executors, administrators, trustees, etc., should indicate the capacity in which signing. If a corporation, please sign in full corporate name by an authorized officer. If a partnership, please sign in partnership name by authorized person. | ||||||||||||||||||||||||
PLEASE VOTE TODAY!
SEE REVERSE SIDE
FOR THREE EASY WAYS TO VOTE.
Important Notice Regarding the Availability of Proxy Materials |
for the Shareholder Meeting To Be Held on Thursday, June 22, 2017 |
The Notice of the Meeting, Proxy Statement, Proxy Card, Annual Report on Form 10-K (as amended) and the |
Dutch Board Report are available at mylan.com/investors
|
q TO VOTE BY MAIL, PLEASE DETACH PROXY CARD HERE, AND SIGN, DATE AND RETURN IN THE ENVELOPE PROVIDED q
Preliminary Copy
MYLAN PROFIT SHARING 401(K) PLAN MYLAN PUERTO RICO PROFIT SHARING EMPLOYEE SAVINGS PLAN VOTING INSTRUCTION FORM
For The Annual General Meeting of Shareholders of Mylan N.V. To Be Held on June 22, 2017 This Voting Instruction Form is Solicited on Behalf of the Board of Directors of Mylan N.V. (the Mylan Board)
PLAN VOTING DEADLINE: [●] Eastern Time (ET), June [●], 2017
The undersigned hereby directs Bank of America, N.A., as trustee for the Mylan Profit Sharing 401(k) Plan, and Banco Popular de Puerto Rico, as trustee for the Mylan Puerto Rico Profit Sharing Employee Savings Plan (together, the Trustees), to appoint [●] and [●], and each with full power to act without the other, as proxies, with full power of substitution, for and in the name of the Trustees to vote and act with respect to all ordinary shares of MYLAN N.V. (Mylan or the Company) credited to the accounts of the undersigned under the above-named plans which the Trustees are entitled to vote and act on behalf of the undersigned at the Annual General Meeting of Shareholders of Mylan to be held on June 22, 2017, with all the powers the Trustees would possess if personally present, and particularly, but without limiting the generality of the foregoing:
IF PROPERLY EXECUTED AND RECEIVED BY THE RELEVANT TRUSTEE PRIOR TO THE PLAN VOTING DEADLINE, THIS VOTING INSTRUCTION FORM WILL BE VOTED FOR EACH DIRECTOR IN ITEM 1 AND FOR ITEMS 2, 3, 4, 5, AND 7 AND 1 YEAR IN ITEM 6 UNLESS A CONTRARY VOTE IS INDICATED, IN WHICH CASE THE PROXY WILL BE VOTED AS DIRECTED.
(Continued and to be signed on the reverse side) |